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Background: Ductal carcinoma in situ (DCIS) of breast is heterogeneous in terms of 
the risk of progression to invasive ductal carcinoma (IDC). To treat DCIS appropriately 
for its progression risk, we classified individual DCIS by its profile of genomic changes 
into 2 groups and correlated them with clinicopathological progression factors. 
Methods: We used surgically resected, formalin-fixed, paraffin-embedded tissues of 22 
DCIS, and 30 IDC lesions. We performed immunohistochemical intrinsic subtyping, 
array-based comparative genomic hybridization and unsupervised clustering. Results: 
The samples were divided into 2 major clusters, A and B. Cluster A showed a greater 
number of gene and chromosome copy-number alterations, a larger IDC/DCIS ratio, a 
higher frequency of non-luminal subtype, a lower frequency of luminal subtype, and a 
higher nuclear grade, when compared with cluster B. But, there was no difference in 
the frequencies of lymph node metastasis between clusters A and B. We identified 9 
breast-cancer related genes, including TP53 and GATA3, that highly contributed to the 
discrimination of A and B clusters. Conclusion: Classification of breast tumors into 
rapidly progressive cluster A and the other (cluster B) may contribute to select the 
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Introduction 
Ductal carcinoma in situ (DCIS) is characterized by noninvasive spreading within 
mammary ducts. Whether DCIS inevitably becomes invasive and what factors 
determine the rate of progression remains unclear. 
In 2011, breast cancer was newly detected in approximately 48,000 Japanese 
women, including 14.2% with DCIS, whereas the percentage of DCIS was only 8.2% in 
2004. This increase in the proportion of DCIS may reflect an increase in the number of 
breast cancer patients who were detected by mammographic screening [1]. 
Mammographic screening is more prevalent in North America than in Japan, and the 
number of DCIS cases detected by screening accounts for nearly 20% of all breast 
cancers in recent years [2]. This increase in DCIS detection is likely to continue until it 
reaches the prevalence of latent DCIS, which is as high as 8.9% of autopsy cases [3]. 
If DCIS inevitably becomes invasive ductal carcinoma (IDC), the screening-based 
detection of DCIS can lead to a reduction in the mortality of breast cancer patients. 
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Many studies reported that screenings had actually reduced breast cancer mortality but 
that the reduction size was smaller than expected probably because of overdiagnosis 
of very dormant tumors as cancers [4, 5]. A retrospective cohort study demonstrated 
that there was no significant difference in the weighted hazard ratios of breast cancer–
specific 10-year survival between surgery and non-surgery groups for low-grade DCIS 
[6]. Accordingly, a follow up study for up to 20 years after a biopsy diagnosis of DCIS 
without subsequent treatment reported that 28% of these patients recurred for IDC 
within approximately 15 years [7]. This study and other similar reports [3, 8] suggest 
that some DCIS lesions remain dormant and have a very slow progression rate to IDC. 
It is also possible that some DCIS lesions do not become invasive. 
Molecular and epidemiological data indicate that breast cancer development is a 
multi-step process [9]. The progression from DCIS to IDC may involve stepwise genetic 
alterations [10, 11]. Some studies have suggested that copy number aberrations 
(CNAs) are associated with the progression from DCIS to IDC, including amplifications 
of MYC[12], FGFR1 [13], and CCND1 [14], which were more frequently observed in 
IDC than DCIS. However, other studies comparing the DCIS and invasive components 
from the same patient demonstrated that CNAs at the chromosome level were very 
similar between intraductal and invasive components [15]. Analogous approaches 
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searching for common transcriptomic and/or genomic differences between matched 
synchronous DCIS and IDC have been unsuccessful [16, 17]. Current studies have 
also failed to identify driver genes that play a significant role in the transition from DCIS 
to IDC [2]. Thus, the presence of progression-related genomic changes and overall 
genomic similarity between DCIS and IDS requires further study. 
In the present study, we focused on the CNA profiles of genomic DNA using array-
based comparative genomic hybridization (CGH). These profiles are unique for 
individual neoplasms because they include random gene alterations that have a neutral 
role for carcinogenesis, accumulate over time based on genetic instability, and are 
selected by the tissue microenvironment. Approximately three-quarters of the natural 
history of solid cancers has elapsed once tumors reach 1 cm in diameter [18], which 
leaves a limited opportunity for the accumulation of additional genomic changes. Thus, 
the CNA profile of clinically detectable breast cancer may already include information 
enough for outcome prediction. In our previous gastric cancer studies, we classified the 
samples based on their CNA profiles using unsupervised hierarchical cluster analyses, 
and demonstrated that nearly all early cancer of the undifferentiated type can become 
advanced [19], whereas approximately 80% of non-invasive neoplasm of the 
differentiated type showed a lineage distinct from advanced cancers [20].  
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  Applying the similar approach to breast cancers, in the present study, we have found 
that breast tumors, including DCIS, IDC and papillomas, were classified into rapidly 
progressive group and slowly progressive group. This classification may contribute to 




The study consisted of 50 patients who underwent a partial or total mastectomy for 
DCIS lesions (n = 22) or IDCs (n = 30; 15 T1, 14 T2, and 1 T4 tumors) from December 
2009 to January 2014 (Supplementary file 1). Two patients had two tumors: 1 patient 
(#13) with bilateral IDC and DCIS and 1 patient (#17) with unilateral IDC and DCIS in 
areas A and C, respectively. All patients were female. The mean age was 55.2 years 
old (range, 35–84 years). None of the patients received any preoperative radio- and/or 
chemotherapy. The conduct in this study was approved by the Institutional Review 
Board at the Shiga University of Medical Science on the condition that the materials 
used remained anonymous (Permission number: 26–36 on July 24, 2014). Written 
informed consent was not required in this retrospective study because of the use of 





We used formalin-fixed, paraffin-embedded (FFPE) tissues. Tissues were fixed in 
buffered 10% formalin for 24 to 48 hours. In 20 of the 30 IDCs, DNA samples were 
taken from both ductal and invasive components. DNA samples of metastatic tumors in 
lymph nodes (LNs) were available in 7 cases (Supplementary file 1). Only patient #18 
had distant metastasis, from which no sample was available. N2 or N3 nodal 
metastasis was not detected in any of the patients in this study. . 
 
Immunohistochemistry and in situ hybridization 
We used 3 µm-thick tissue sections for the immunohistochemical (IHC) analysis of 
the estrogen receptor (ER), progesterone receptor (PgR), HER2, basal and 
myoepithelial markers (cytokeratin (CK) 5/6 and p63), and Ki-67. We used the following 
antibodies: anti-ER (clone 1D5, DAKO, Santa Clara, CA, USA; dilution 1:50), anti-PgR 
(clone PgR636, DAKO; dilution 1:50), anti-Ki-67 (clone MM1, Leica Biosystems 
Newcastle Ltd, Newcastle Upon Tyne, UK; dilution 1:100), anti-HER2 (clone 4B5, 
Ventana, Tucson, AZ, USA; pre-diluted), and anti-CK5/6 and anti-p63 (based on a 
previous study) [21]. IHC was optimized by evaluating serial sections with multiple 
8 
 
antibody concentrations using a Discovery Automated Immunostainer (Ventana 
Medical Systems, Tucson, AZ, USA).  
For Her2 testing, dual-color fluorescence in situ hybridization (FISH), using the 
PathVysion HER-2 DNA Probe Kit (PathVysion; Abbott Molecular, Des Plaines, IL, 
USA), and IHC were used in accordance with the guidelines of the American Society of 
Clinical Oncology (ASCO) [22]. After counting the signals of Her2 and those of 
centromeric enumeration probe 17 (CEP17) under a fluorescence microscope, a 
Her2/CEP17 ratio ≥ 2.0 was defined as amplification. 
 
Genomic DNA extraction  
Tumor and normal lymph node (reference) samples were obtained from 5 µm-thick 
tissue sections using a laser microdissection system (LMD6000; Leica Microsystems, 
Wetzlar, Germany) [20]. Briefly, each sample was dissected from an area ≥6 mm2. In 
tumor samples, neoplastic cells comprised 90% of the total cell count. The cells were 
digested with a 200 mg/mL proteinase K solution (P2308, Sigma-Aldrich, St. Louis, 
MO, USA) for 70 ± 2 h at 37°C prior to a phenol/chloroform DNA extraction. DNA 
quality was assessed based on the A260/A280 ratio (cut-off >1.5), A260/A230 ratio 




Whole genome amplification (WGA) 
Sample DNA was amplified using the GenomePlex Whole Genome Amplification Kit 
(WGA2 Kit; Sigma, St. Louis, MO, USA) according to the manufacturer’s protocol [23]. 
 
Array CGH 
For genomic DNA analysis, a 60-mer oligonucleotide CGH microarray (Agilent, Santa 
Clara, CA, USA) was used according to the manufacturer’s instructions [24]. The 
genomic DNA enzymatic labelling and subsequent array CGH was performed as 
previously described [20]. The tumor-to-reference fluorescence intensity ratio (T/R) was 
calculated from the hybridized array images obtained. The UCSC Genome Browser 
was used with the latest resource content: hg19 assembly - Design ID 021429 (GRCh 
Build 37). CNAs were defined as a gain, loss, and amplification when the base 2 
logarithm of the T/R ratio was >0.3219, <−0.3219, and >1.0, respectively. The 
microarray data were registered in the Gene Expression Omnibus (GEO) database 




Validation of array CGH data by fluorescence in situ hybridization 
Using the samples positive for ERBB2 gene amplification, we compared FISH signal 
numbers and the T/R ratio of the array CGH. For dual-color FISH for ERBB2 gene 
amplification, we used PathVysion Her2 DNA Probe Kit, (Abbot Molecular Inc.). We 
randomly selected 7 and 8 samples from the sample groups that showed strong (3+) 
and weak (1+ or 2+) Her2 immunoreactivities, respectively.  
 
Clustering algorithm 
To enhance the signal-to-noise ratio in the hybridization analysis, we averaged the 
T/R ratio of the probes within each gene prior to performing the cluster analyses. The 
noise-canceling effect of averaging depends on the gene size (probe number within the 
gene), whereas the clustering reproducibility becomes lower as the gene number 
becomes smaller. Notably, larger gene sizes correspond to smaller gene numbers. 
Thus, we repeated the clustering analysis to determine the optimal gene size and 
number.  
To classify samples based solely on genome-wide similarities in gene copy-number 
gain/loss patterns, we performed an unsupervised hierarchical cluster analysis using a 
free software program (Cluster 3.0, version 1.52 and TreeView, version 1.1.6r2). The 
clustering results were assessed as previously described [20, 25, 26]. Briefly, we 
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repeated the clustering analysis using genes ranging from 370 genes containing ≥10 
probes to 9,487 genes containing ≥2 probes. We selected 2 gene size conditions that 
showed the highest reproducibility in clustering dendrograms, and then selected the 
condition with the highest proportion of sample sets that derived from the same tumor 
and showed the neighboring in the clustering dendrogram.  
The clustering condition was set to a complete linkage (maximum of distance metric 
on similarities) and the uncentered correlation distance (distance measures based on 
modified Pearson’s correlation).  
 
Statistical analysis 
The CNA differences for each gene between clusters A and B were statistically 
assessed in an unequal sample-size t-test (Welch’s t-test). A bilateral p-value of ≤0.05 
was considered statistically significant. For multiple comparisons, the t test was 
subsequently adjusted using the Bonferroni correction [25] (Microsoft Office Excel 
2013). To assess trend differences in either nuclear atypia or CNA accumulations 
between the 2 groups, a Fisher’s exact test (2 × 2 contingency tables) was performed 






The intrinsic subtype was estimated immunohistochemically on the basis of the 
clinico-pathological surrogate definitions of subtypes based on the 2013 St Gallen 
Consensus [27]; immunohistochemistry-based definition of luminal A-like tumors is ER-
positive, HER2-negative, Ki-67 index less than 14% and PR positivity more than 20% 
[28]. The 81 carcinoma samples were classified into 20 luminal A-like, 37 luminal B-like 
(HER2 negative), 6 luminal B-like (HER2 positive), 6 HER2 positive (non-luminal), and 
12 triple negative (ductal).  
 
Association of chromosomal CNAs with clinicopathological factors 
IDC and DCIS commonly showed gains of 1q, 5p, 8q, 11q13, 16p, 17q, and 21q and 
losses of 4q, 8p, distal 11q, 13q, 14q, 16q, 17p, and 22q, but different in the 
frequencies of 6q−, 11q−, and 22q− (Fig. 1a-d, Table 1). The chromosomal CNAs 
different in frequency between NG1 and NG2/3 samples, were 4q−, 16q−, and 22q− 
(Fig. 1e,f, Table 2a). Those different between luminal-like (ER+) and non-luminal-like 
(ER−) subtypes were 4q−, 7p+, 8q+, 10p+, 16q−, and 21q+ (Fig.1g, h, Table 2b). Only 
16q− was significantly different in frequency between the samples of N0 and N1 tumors 
(Fig.1i, j, Table 3).  
13 
 
Amplifications of 17q12 were found in 9/12 of the tumor samples that showed strong 
(3+) immunohistochemical expression of HER2 irrespective of DCIS or IDC.  
 
Validation of array CGH data by fluorescence in situ hybridization 
In the 7 samples with strong Her2 immunoreactivity, the T/R ratios of ERBB2 gene 
were 1.81 to 3.12 (average 2.53) and the FISH signal ratio was 2.4 to 5.8 (average 
4.2). In the 8 samples with weak Her2 immunoreactivity, the T/R ratios of ERBB2 gene 
were -0.93 to 0.03 (average -0.24), and the FISH signal ratio was 0.9 to 1.3 (average 
1.05), No gene amplification is detected in the samples with weak HER2 
immunoreactivity, and vice versa. 
 
Clustering of gene copy-number profiles 
The individual probe T/R ratios within a specified gene were averaged. The average 
T/R ratios of 30,471 gene regions were calculated from 55,023 probes. Genes selected 
based on size were subjected to an unsupervised hierarchical cluster analysis. After 
repeated clustering using varying minimum gene sizes, we found that the gene sizes of 
≥3 probes and ≥4 probes gave highest reproducibility of clustering results 
(Supplementary file 2). In the condition of a gene size ≥4 probes, all samples from the 
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same case were in the neighboring position in the clustering dendrogram, confirming 
the reproducibility of the CNA profile. Thus, we adopted this as the optimal condition for 
the unsupervised hierarchical clustering of all (cancer and papilloma) samples. This 
condition yielded 2 main clusters: A and B (Fig. 2). The cancer samples of cluster A 
showed a greater IDC/DCIS ratio, a higher ER−/ER+ (non-luminal/luminal) ratio, and 
higher nuclear grade than those in cluster B (Table 4). There were also tendencies for 
higher Ki-67 index, higher triple negative tumors in Cluster A. There was no difference 
in the frequency of lymph node metastasis between the clusters A and B. 
 
Lineage-specific chromosomal CNA profile 
The penetrance plots of clusters A and B revealed distinct chromosomal CNA profiles 
(Fig. 3). In addition to changes common to these clusters (a gain of 1q and stage-
specific losses of 6q and 16q), cluster A was characterized by gains of 5p, 16p, and 
21q and losses of 4p and 8p, whereas cluster B scarcely showed these changes (Table 
2c).  
 
Genes exhibiting significantly different CNAs between 2 major clusters 
We extracted 728 genes that show significantly different mean copy numbers 
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between clusters A and B in a t-test with Bonferroni correction. Out of the top 45 genes 
shown in Supplementary file 3a, 42 were protein-coding, including 10 genes that 
showed concordance between the gene CNA and chromosome CNA in cluster A. In 7 
of these 10 genes, gene function was relevant to the direction of CNA, i.e., gain and 
loss of protooncogene and tumor suppressor genes, respectively. These 7 genes 
included the proto-oncogene, LMO3, which reportedly plays a role in T cell leukemia 
and brain tumors. The other 3 genes, which included PIK3R5, showed a loss of gene 
and chromosome copy number. Notably, this loss is functionally opposite because the 
genes are protooncogenic. These genes may be passenger genes, and thus only 
useful as a lineage marker for the differentiation of clusters A and B.  
Of the 93 genes that were reported to be important in a next generation sequencing 
analysis of breast cancers [29], 44 genes showed statistically significant differences in 
the mean CNA between clusters A and B (Supplementary file 3b), and 9 genes 
(GATA3, TP53, TET2, NCOR1, NOTCH2, PIC3CA, CREBBP, MYC, and ERBB2 in 
decreasing order of significance) showed concordance between both the gene and 
chromosome CNAs and the function and gain/loss of genes. Of these genes, only 
GATA3 and TP53 remained significant after Bonferroni correction. GATA3 gain and 





For validation of array CGH data, we utilized the samples with and without the 
overexpression (3+) of Her 2 protein and demonstrated almost complete concordance 
between array CGH and FISH results. In the absence of gene amplification, 
quantitative polymerase chain reaction (qPCR) as well as FISH is difficult to use for the 
validation of CNAs [20]. We attempted to cancel the noise inherent to FFPE tissues by 
averaging the T/R ratio of larger-sized genes. Using the internal standard mentioned in 
Methods, we optimized the gene size for the assessment of gene-level copy number 
alterations. Applying this method to the present breast cancer samples, we found 2,828 
genes of ≥4 probes as the optimal condition for unsupervised clustering. 
Next generation sequencing (NGS) showed that gene copy-number changes are 
more common than significant DNA sequence changes in cancers [29]. Additionally, 
recent NGS-based approaches to tumor heterogeneity demonstrated that 
chromosomal CNAs are the principal factor for tumor progression, whereas sequence 
changes of driver genes as well as chromosomal CNAs are important for the earlier 
phases of carcinogenesis [30]. In the present chromosome-level CNA analysis, our 
penetrance plot of IDC (invasive part) showed a gain/loss pattern very similar to recent 
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NGS data of 560 breast cancers [29], except for 9q loss, which was observed less 
frequently in our study.  
The chromosomal CNA profiles were similar between DCIS and IDC, as previously 
reported [15, 31], except for the scarcity of losses in 6q, 11q, and 22q in DCIS (Table 
1). Gains of 5p, 7, 11q, 16p, and 20q and a loss of 8p were previously reported to be 
more frequent in IDC than DCIS [32, 33]. In the present study, however, none of them 
showed statistically significant difference between DCIS and IDC. Other 
clinicopathological factors were correlated with characteristic chromosomal changes 
(Tables 2 and 3): 22q− correlated with high NG; 7p+, 8q+, and 10p+ with non-luminal-
like (ER−) subtypes; the absence of 16q− with lymph node metastasis. The 8q+, 17q+, 
and 8p− reported to be common in high-grade breast cancers [31] were not significant 
in our results. CNAs, including a gain of 1q and loss of 16q, were detected in nearly 
50% of IDCs and 25% of DCIS. All samples with both 1p+ and 16q− were luminal-like 
(ER+) type, as previously reported [34]. Problem is whether these changes are useful 
for the specification of progression-prone DCIS. Table 1 demonstrates that neither NG 
nor intrinsic subtype showed significant correlation with an IDC/DCIS ratio, which may 
be related to the risk of progression from DCIS to IDC. Thus, we analyzed the following 
gene-level CNAs to assess the outcome of individual tumors. 
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Under the above-mentioned optimal condition, the unsupervised hierarchical 
clustering gave 2 main clusters for all (cancer and papilloma) samples: A and B. The 
cancer samples of cluster A showed a greater frequency of chromosomal gain and 
loss, a greater IDC/DCIS ratio, a higher non-luminal-like/luminal-like (ER−/ER+) ratio 
and higher nuclear grade than cluster B (Table 4). Thus, the tumors of cluster A may be 
phenotypically less differentiated, and have accumulated a greater number of genomic 
changes (Figs. 2 and 3), reflecting higher level of genomic instability. The DCIS lesions 
in cluster A that correlates with high NG may be more progression-prone to IDC than 
those in cluster B. This is consistent with the previous notion that nuclear grade largely 
paralleled the total number of gene CNAs and the risk of progression from DCIS to IDC 
[31, 35].  
However, there was no difference in the frequency of lymph node metastasis 
between clusters A and B (Table 4) as well as between low and high NG and between 
ER+ and ER− tumors (Table 3). Additionally, Table 3 demonstrated that the 
accumulation of chromosomal CNAs was scarcely different between N0 and N1 
samples. The only chromosomal CNA significantly different between N0 and N1 was 
the absence of 16q loss in metastasis samples. This suggests that the metastasis risk 
might be determined in earlier phase of tumor development because the 16q loss is 
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common early event in breast carcinomas (Fig. 1). This point, whether 16q copy 
number is useful in the prediction of metastasis risk should be further studied using 
larger breast cancer cohorts.  
It seems that the metastasis risk and the progression risk form DCIS to IDC reflect 
different genomic and epigenomic features. In stomach cancers, we similarly found that 
the copy-number profiling approach could stratified tumor samples into rapidly and 
slowly progressive 2 groups, but no difference in metastasis risk was shown between 
these groups, whereas, different from the present study, metastatic gastric samples 
accumulated later chromosomal CNAs more frequently than the samples without 
metastasis (unpublished data).   
Of the 30,471 gene regions, 728 showed significant copy-number differences 
between clusters A and B. Among them, 9 genes (TP53, GATA3, CDKN2A, ATR, ATRX, 
PHF6, SMARCA4, APC, and ASXL1) were included in the breast cancer-related 93 
genes [29]. Of these 9 genes, only TP53 and GATA3 [36] remained significant after the 
Bonferroni correction and showed concordance between gene and chromosome 
changes and between gain/loss and gene function. The other genes showed 
discordance between gene function and copy-number changes, and thus may be 
passenger genes (Supplrmentary file 3b). Recent meta-analysis of 10 articles reported 
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that GATA3 expression was associated with better prognosis [37]. This seems 
contradictory to our result that invasion-prone tumors often showed GATA3 copy-
number gain. In our unpublished data, copy-number changes of GATA3 were not in 
parallel with its IHC results, which may reflect epigenetic regulations. 
Still currently, screening-positive patients are often treated with additional 
radiotherapy after segmental surgical excision. Such postoperative therapies can be 
individualized based on the progression risk of each DCIS; the targets can be 
pinpointed to invasion-prone DCIS, as detected in the present study. The genes we 
specified could be useful for a construction of a simple system for pinpointing the 
invasion-prone DCIS.   
   
References 
1 Kurebayashi J, Miyoshi Y, Ishikawa T, Saji S, Sugie T, Suzuki T, Takahashi S, 
Nozaki M, Yamashita H, Tokuda Y, Nakamura S: Clinicopathological 
characteristics of breast cancer and trends in the management of breast 
cancer patients in Japan: Based on the Breast Cancer Registry of the 
Japanese Breast Cancer Society between 2004 and 2011. Breast Cancer 
2015;22:235-244. 
 
2 Cowell CF, Weigelt B, Sakr RA, Ng CK, Hicks J, King TA, Reis-Filho JS: 
Progression from ductal carcinoma in situ to invasive breast cancer: 
revisited. Mol Oncol 2013;7:859-869. 
 
3 Welch HG, Black WC: Using autopsy series to estimate the disease 
21 
 
&quot;reservoir&quot; for ductal carcinoma in situ of the breast: how much 
more breast cancer can we find? Ann Intern Med 1997;127:1023-1028. 
 
4 Screening IUPoBC: The benefits and harms of breast cancer screening: an 
independent review. Lancet 2012;380:1778-1786. 
 
5 Welch HG, Black WC: Overdiagnosis in cancer. J Natl Cancer Inst 
2010;102:605-613. 
 
6 Sagara Y, Mallory MA, Wong S, Aydogan F, DeSantis S, Barry WT, Golshan M: 
Survival Benefit of Breast Surgery for Low-Grade Ductal Carcinoma In Situ: A 
Population-Based Cohort Study. JAMA Surg 2015 
 
7 Page DL, Dupont WD, Rogers LW, Jensen RA, Schuyler PA: Continued local 
recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal 
carcinoma in situ of the breast treated only by biopsy. Cancer 
1995;76:1197-1200. 
 
8 Stuart KE, Houssami N, Taylor R, Hayen A, Boyages J: Long-term outcomes 
of ductal carcinoma in situ of the breast: a systematic review, meta-analysis 
and meta-regression analysis. BMC Cancer 2015;15:890. 
 
9 Leonard GD, Swain SM: Ductal carcinoma in situ, complexities and 
challenges. J Natl Cancer Inst 2004;96:906-920. 
 
10 Amari M, Moriya T, Ishida T, Harada Y, Ohnuki K, Takeda M, Sasano H, Horii 
A, Ohuchi N: Loss of heterozygosity analyses of asynchronous lesions of 
ductal carcinoma in situ and invasive ductal carcinoma of the human breast. 
Jpn J Clin Oncol 2003;33:556-562. 
 
11 Yen MF, Tabár L, Vitak B, Smith RA, Chen HH, Duffy SW: Quantifying the 
potential problem of overdiagnosis of ductal carcinoma in situ in breast 
cancer screening. Eur J Cancer 2003;39:1746-1754. 
 
12 Robanus-Maandag EC, Bosch CA, Kristel PM, Hart AA, Faneyte IF, Nederlof 
PM, Peterse JL, van de Vijver MJ: Association of C-MYC amplification with 
22 
 
progression from the in situ to the invasive stage in C-MYC-amplified breast 
carcinomas. J Pathol 2003;201:75-82. 
 
13 Jang M, Kim E, Choi Y, Lee H, Kim Y, Kim J, Kang E, Kim SW, Kim I, Park S: 
FGFR1 is amplified during the progression of in situ to invasive breast 
carcinoma. Breast Cancer Res 2012;14:R115. 
 
14 Burkhardt L, Grob TJ, Hermann I, Burandt E, Choschzick M, Jänicke F, Müller 
V, Bokemeyer C, Simon R, Sauter G, Wilczak W, Lebeau A: Gene 
amplification in ductal carcinoma in situ of the breast. Breast Cancer Res 
Treat 2010;123:757-765. 
 
15 Hernandez L, Wilkerson PM, Lambros MB, Campion-Flora A, Rodrigues DN, 
Gauthier A, Cabral C, Pawar V, Mackay A, A'hern R, Marchiò C, Palacios J, 
Natrajan R, Weigelt B, Reis-Filho JS: Genomic and mutational profiling of 
ductal carcinomas in situ and matched adjacent invasive breast cancers 
reveals intra-tumour genetic heterogeneity and clonal selection. J Pathol 
2012;227:42-52. 
 
16 Vincent-Salomon A, Lucchesi C, Gruel N, Raynal V, Pierron G, Goudefroye R, 
Reyal F, Radvanyi F, Salmon R, Thiery JP, Sastre-Garau X, Sigal-Zafrani B, 
Fourquet A, Delattre O, Curie bcsgotI: Integrated genomic and 
transcriptomic analysis of ductal carcinoma in situ of the breast. Clin Cancer 
Res 2008;14:1956-1965. 
 
17 Liao S, Desouki MM, Gaile DP, Shepherd L, Nowak NJ, Conroy J, Barry WT, 
Geradts J: Differential copy number aberrations in novel candidate genes 
associated with progression from in situ to invasive ductal carcinoma of the 
breast. Genes Chromosomes Cancer 2012;51:1067-1078. 
 
18 Friberg S, Mattson S: On the growth rates of human malignant tumors: 
implications for medical decision making. J Surg Oncol 1997;65:284-297. 
 
19 Sonoda A, Mukaisho K, Nakayama T, Diem VT, Hattori T, Andoh A, Fujiyama 
Y, Sugihara H: Genetic lineages of undifferentiated-type gastric carcinomas 
analysed by unsupervised clustering of genomic DNA microarray data. BMC 
23 
 
Med Genomics 2013;6:25. 
 
20 Vo DT, Nakayama T, Yamamoto H, Mukaisho K, Hattori T, Sugihara H: 
Progression risk assessments of individual non-invasive gastric neoplasms by 
genomic copy-number profile and mucin phenotype. BMC Med Genomics 
2015;8:6. 
 
21 Furuya C, Kawano H, Yamanouchi T, Oga A, Ueda J, Takahashi M: Combined 
evaluation of CK5/6, ER, p63, and MUC3 for distinguishing breast intraductal 
papilloma from ductal carcinoma in situ. Pathol Int 2012;62:381-390. 
 
22 Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, 
Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu 
PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF, 
Oncology ASoC, Pathologists CoA: Recommendations for human epidermal 
growth factor receptor 2 testing in breast cancer: American Society of 
Clinical Oncology/College of American Pathologists clinical practice guideline 
update. Arch Pathol Lab Med 2014;138:241-256. 
 
23 Little SE, Vuononvirta R, Reis-Filho JS, Natrajan R, Iravani M, Fenwick K, 
Mackay A, Ashworth A, Pritchard-Jones K, Jones C: Array CGH using whole 
genome amplification of fresh-frozen and formalin-fixed, paraffin-embedded 
tumor DNA. Genomics 2006;87:298-306. 
 
24 Barrett MT, Scheffer A, Ben-Dor A, Sampas N, Lipson D, Kincaid R, Tsang P, 
Curry B, Baird K, Meltzer PS, Yakhini Z, Bruhn L, Laderman S: Comparative 
genomic hybridization using oligonucleotide microarrays and total genomic 
DNA. Proc Natl Acad Sci U S A 2004;101:17765-17770. 
 
25 Eisen MB, Spellman PT, Brown PO, Botstein D: Cluster analysis and display 
of genome-wide expression patterns. Proc Natl Acad Sci U S A 
1998;95:14863-14868. 
 





27 Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, 
Thürlimann B, Senn HJ, members P: Personalizing the treatment of women 
with early breast cancer: highlights of the St Gallen International Expert 
Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 
2013;24:2206-2223. 
 
28 Prat A, Cheang MC, Martín M, Parker JS, Carrasco E, Caballero R, Tyldesley 
S, Gelmon K, Bernard PS, Nielsen TO, Perou CM: Prognostic significance of 
progesterone receptor-positive tumor cells within immunohistochemically 
defined luminal A breast cancer. J Clin Oncol 2013;31:203-209. 
 
29 Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, 
Martincorena I, Alexandrov LB, Martin S, Wedge DC, Van Loo P, Ju YS, Smid 
M, Brinkman AB, Morganella S, Aure MR, Lingjærde OC, Langerød A, Ringnér 
M, Ahn SM, Boyault S, Brock JE, Broeks A, Butler A, Desmedt C, Dirix L, 
Dronov S, Fatima A, Foekens JA, Gerstung M, Hooijer GK, Jang SJ, Jones DR, 
Kim HY, King TA, Krishnamurthy S, Lee HJ, Lee JY, Li Y, McLaren S, Menzies 
A, Mustonen V, O'Meara S, Pauporté I, Pivot X, Purdie CA, Raine K, 
Ramakrishnan K, Rodríguez-González FG, Romieu G, Sieuwerts AM, Simpson 
PT, Shepherd R, Stebbings L, Stefansson OA, Teague J, Tommasi S, Treilleux 
I, Van den Eynden GG, Vermeulen P, Vincent-Salomon A, Yates L, Caldas C, 
van't Veer L, Tutt A, Knappskog S, Tan BK, Jonkers J, Borg Å, Ueno NT, 
Sotiriou C, Viari A, Futreal PA, Campbell PJ, Span PN, Van Laere S, Lakhani 
SR, Eyfjord JE, Thompson AM, Birney E, Stunnenberg HG, van de Vijver MJ, 
Martens JW, Børresen-Dale AL, Richardson AL, Kong G, Thomas G, Stratton 
MR: Landscape of somatic mutations in 560 breast cancer whole-genome 
sequences. Nature 2016;534:47-54. 
 
30 Uchi R, Takahashi Y, Niida A, Shimamura T, Hirata H, Sugimachi K, Sawada 
G, Iwaya T, Kurashige J, Shinden Y, Iguchi T, Eguchi H, Chiba K, Shiraishi Y, 
Nagae G, Yoshida K, Nagata Y, Haeno H, Yamamoto H, Ishii H, Doki Y, 
Iinuma H, Sasaki S, Nagayama S, Yamada K, Yachida S, Kato M, Shibata T, 
Oki E, Saeki H, Shirabe K, Oda Y, Maehara Y, Komune S, Mori M, Suzuki Y, 
Yamamoto K, Aburatani H, Ogawa S, Miyano S, Mimori K: Integrated 
Multiregional Analysis Proposing a New Model of Colorectal Cancer Evolution. 




31 Lopez-Garcia MA, Geyer FC, Lacroix-Triki M, Marchió C, Reis-Filho JS: Breast 
cancer precursors revisited: molecular features and progression pathways. 
Histopathology 2010;57:171-192. 
 
32 Yao J, Weremowicz S, Feng B, Gentleman RC, Marks JR, Gelman R, Brennan 
C, Polyak K: Combined cDNA array comparative genomic hybridization and 
serial analysis of gene expression analysis of breast tumor progression. 
Cancer Res 2006;66:4065-4078. 
 
33 Anbazhagan R, Fujii H, Gabrielson E: Allelic loss of chromosomal arm 8p in 
breast cancer progression. Am J Pathol 1998;152:815-819. 
 
34 Buerger H, Otterbach F, Simon R, Schäfer KL, Poremba C, Diallo R, 
Brinkschmidt C, Dockhorn-Dworniczak B, Boecker W: Different genetic 
pathways in the evolution of invasive breast cancer are associated with 
distinct morphological subtypes. J Pathol 1999;189:521-526. 
 
35 Fidalgo F, Rodrigues TC, Pinilla M, Silva AG, Maciel MoS, Rosenberg C, de 
Andrade VP, Carraro DM, Krepischi AC: Lymphovascular invasion and 
histologic grade are associated with specific genomic profiles in invasive 
carcinomas of the breast. Tumour Biol 2015;36:1835-1848. 
 
36 Takaku M, Grimm SA, Wade PA: GATA3 in Breast Cancer: Tumor Suppressor 
or Oncogene? Gene Expr 2015;16:163-168. 
 
37 Guo Y, Yu P, Liu Z, Maimaiti Y, Chen C, Zhang Y, Yin X, Wang S, Liu C, Huang 
T: Prognostic and clinicopathological value of GATA binding protein 3 in 




Figure 1 Penetrance plots. a. ductal carcinoma in situ (DCIS, 24 samples); b. ductal 
part of invasive ductal carcinoma (IDC) (Cd, 22 samples); c. invasive part of IDC (Ci, 
26 
 
28 samples); d. nodal metastatic tumors of IDC (CL, 7 samples); e. low nuclear grade 
(NG1, 22 samples); f. high nuclear grade (NG2,3, 59 sample); g: luminal subtype (ER+, 
63 samples); h. (non-luminal subtype (ER−, 18 samples); i. nodal metastasis absent 
(N−, 37 samples); j. nodal metastasis present (N+, 20 samples). Yellow squares mark 
statistically significant changes. 
 
Figure 2 Unsupervised, hierarchical clustering using 81 samples and 2828 larger 
genes that contain ≥4 probes. The abbreviations of samples, D, Ci, Cd and CL indicate 
ductal carcinoma in situ (DCIS), ductal part of invasive ductal carcinoma (IDC), 
invasive part of IDC and lymph node metastasis, respectively. Copy-number gains and 
losses are indicated by green and red squares, respectively in the heat map. Beneath 
the dendrogram are 3 color bars. The top, the middle and the bottom indicate nuclear 
grade (dark green NG3; light green, NG2; yellow, NG1), intrinsic subtype (red, Her2; 
pink, luminal A; light blue, luminal B; gray, triple negative; green) and tumor 
stage (white, IDC; gray, DCIS), respectively. Blue squares indicate sample groups of 
the same case)  
 
Figure 3 Cluster-specific penetrance plots of ductal carcinomas. A. cluster A (50 
27 
 




Supplementary file 1 Clinicopathological data of samples (XLSX 16 kb) 
 
Supplementary file 2 Clustering dendrograms with varying gene numbers and sizes. 
These ranged from 9487 genes containing ≥2 probes to 370 genes containing ≥10 
probes. Red horizontal lines indicate the border of 2 major clusters. (PDF 159 kb) 
 
Supplementary file 3 a. The top 45 genes with highly different mean copy numbers 
between clusters A and B. The gene are arranged in a decreasing order of significance. 
b. A list of 44 breast cancer-related genes [32], which showed significantly different 
mean copy numbers between clusters A and B. The 9 genes above the horizontal line 
remain significant after Bonferroni correction. In a and b, the order of samples is the 
same as that in Fig. 2. The copy number of each gene is shown as the tumor/reference 
fluorescence ratio. The orange and moss green indicate copy-number gain and loss, 
respectively. In the columns of chromosome arms, pink and deep green indicate gain 
and loss respectively. Light pink and light green indicate slight changes. The column of 
28 
 
concordance shows concordance or discordance of copy-number changes between 
gene and chromosome levels. The column of relevance shows whether the copy-
number changes are concordant to gene function for the expression of malignant 
phenotype. (PDF 1062 kb) 
P 
Low NG (1) 10 12 0.0986
High NG (2,3) 14 45
ER+ (Luminal A/B (Her2+/−)) 20 43 0.5637
ER− (Her2+/TN) 4 14
6q− 0 10 0.0290
absent 24 47
8p− 2 13 0.2094
absent 22 44
11q− 1 16 0.0167
absent 23 41
16p+ 2 10 0.4943
absent 22 47
20q+ 1 5 0.6641
absent 23 52
22q− 1 15 0.0300
absent 23 40
Table 1. Comparisons of clinicopathological features and chromosomal
changes between DCIS and IDC samples.
DCIS IDC
22 63 18 50 31
1q+ 21 9 0.7966 25 3 0.0938 17 11 1.0000
4p− 10 1 0.2731 5 6 0.0110 11 0 0.0055
4q− 13 0 0.0157 6 7 0.0067 10 3 0.3511
5p+ 8 1 0.432 6 3 0.4083 9 0 0.0112
7p+ 6 0 0.1824 2 4 0.0201 6 0 0.0774
8p− 12 3 0.7486 9 6 0.3399 15 0 0.0003
8q+ 13 1 0.0975 5 9 0.0201 11 3 0.1466
10p+ 6 0 0.1824 1 5 0.0017 6 0 0.0783
13q− 7 3 1.0000 10 0 0.1067 6 4 1.0000
14q− 8 0 0.0999 6 2 1.0000 7 1 0.1453
16p+ 11 1 0.1648 7 5 0.1262 11 1 0.0267
16q− 14 12 0.0148 25 1 0.0083 13 13 0.1501
17p− 13 1 0.0975 11 3 1.0000 12 2 0.0675
21q+ 7 0 0.1809 2 5 0.0052 7 0 0.0401
22q− 16 0 0.0042 14 2 0.5027 10 6 1.0000
Table 2: Differences in sample-based frequencies of chromosomal copy-number changes between high nad low nuclear grade (a), between












Low NG (1) 9 3 0.5098
High NG (2,3) 28 17
ER+ (Luminal A/B (Her2+/−)) 31 12 0.0594
ER− (Her2+/TN) 6 8
4p− 7 4 1.0000
absent 30 16
5p+ 3 3 0.6542
absent 34 17
6q− 4 6 0.1410
absent 33 14
14q− 5 3 1.0000
absent 32 17
16q− 17 2 0.0077
absent 20 18
17p− 8 6 0.7651
absent 29 18
22q− 10 6 1.0000
absent 27 14
Table 3. Comparisons of clinicopathological features and chromosomal
changes between N0 and N1 samples of 57 invasive ductal carcinomas
N0 N1
PMean gain regions 8.7 1.9 0.0023
Mean loss regions 6.2 2.2 0.0143
DCIS* 10 14 0.0239
IDC* 40 17
Low NG (1)* 7 15 0.0016
High NG (2,3)* 43 16
ER+ (Luminal A/B (Her2+/−))* 34 29 0.0117
ER− (Her2+/TN)* 16 2
Mean Ki-67 index of cancer cells 12.6 9.5 0.0672
N+ in IDC cases (30) 6 3 1.0000
N− 15 6
N+ in IDC samples (57)* 14 6 1.0000
N−* 26 11
* Described in sample numbers
B (n=31)A (n=50)











































































































































































































































































































































































No. Age TNM Stage Component
Nuclear
atypia
ER(%) PgR(%) HER2 MIB-I(%) Subtype
#1 C1i 49 1/0/0 I Invasive 2 0 0 3 29 HER2 positive(non-luminal)
#1 C1d Ductal 3 0 0 3 15 HER2 positive(non-luminal)
#2 C2i 53 2/0/0 IIA Invasive 2 30 0 0 37 Luminal B-like(HER2 negative)
#2 C2d Ductal 2 12 0 0 30 Luminal B-like(HER2 negative)
#3 C3i 62 1/0/0 I Invasive 2 100 0 1 6 Luminal B-like(HER2 negative)
#3 C3d Ductal 2 100 0 0 6 Luminal B-like(HER2 negative)
#4 C4i 62 2/0/0 IIA Invasive 2 80 0 1 2 Luminal B-like(HER2 negative)
#4 C4d-m Ductal 2 90 0 1 5 Luminal B-like(HER2 negative)
#4 C4d-s Ductal 2 90 0 1 5 Luminal B-like(HER2 negative)
#5 C5i 62 1/1/0 IIA Invasive 1 100 1 1 7 Luminal B-like(HER2 negative)
#5 C5d Ductal 1 100 70 0 3 Luminal A-like
#6 C6i 83 1/0/0 I Invasive 2 100 0 3 13 Luminal B-like(HER2 positive)
#6 C6d Ductal 1 100 1 2 6 Luminal B-like(HER2 negative)
#7 C7i 37 1/1/0 IIA Invasive 2 99 90 0 17 Luminal B-like(HER2 negative)
#7 C7d Ductal 2 100 60 1 5 Luminal A-like
#7 C7L LNs meta 2 100 40 0 27 Luminal B-like(HER2 negative)
#8 C8i 43 2/0/0 IIA Invasive 1 90 90 1 13 Luminal A-like
#8 C8d Ductal 1 99 100 1 7 Luminal A-like
#9 C9i 35 1/0/0 I Invasive 2 98 0 0 25 Luminal B-like(HER2 negative)
#9 C9d Ductal 1 100 0 0 8 Luminal B-like(HER2 negative)
#10 C10i 46 1/0/0 I Invasive 1 98 90 1 33 Luminal B-like(HER2 negative)
#11 C11i 73 1/0/0 I Invasive 2 100 50 0 15 Luminal B-like(HER2 negative)
#12 C12i 50 1/0/0 I Invasive 1 98 40 1 9 Luminal A-like
#12 C12d Ductal 1 98 10 0 4 Luminal B-like(HER2 negative)
#13 C13i-w1 57 1/1/0 IIA Invasive 1 100 70 0 16 Luminal B-like(HER2 negative)
#13 C13L-w1 LNs meta 2 100 90 0 15 Luminal B-like(HER2 negative)
#14 C14i 47 2/1/0 IIB Invasive 2 70 0 0 10 Luminal B-like(HER2 negative)
#14 C14d Ductal 2 80 0 0 5 Luminal B-like(HER2 negative)
#14 C14L LNs meta 2 90 10 0 10 Luminal B-like(HER2 negative)
#15 C15i 45 1/0/0 I Invasive 1 70 10 1 10 Luminal B-like(HER2 negative)
#15 C15d Ductal 1 80 20 1 10 Luminal A-like
#16 C16i 52 1/0/0 I Invasive 2 50 90 1 18 Luminal B-like(HER2 negative)
#16 C16d Ductal 2 50 80 1 20 Luminal B-like(HER2 negative)
#17 C17i-w2 84 1/0/0 I Invasive 2 100 0 0 5 Luminal B-like(HER2 negative)
#17 C17d-w2 Ductal 2 100 30 0 3 Luminal A-like
#18 C18i 81 2/1/1 IV Invasive 3 0 0 1 20 Triple negative
#18 C18d Ductal 3 0 0 1 20 Triple negative
#18 C18L LNs meta 3 0 0 1 18 Triple negative
#19 C19i 51 2/1/0 IIB Invasive 3 70 5 3 15 Luminal B-like(HER2 positive)
#19 C19d Ductal 3 70 5 3 14 Luminal B-like(HER2 positive)
#20 C20i 42 1/0/0 I Invasive 2 90 5 0 10 Luminal B-like(HER2 negative)
#20 C20d Ductal 2 90 5 0 5 Luminal B-like(HER2 negative)
#21 C21i 63 2/0/0 IIA Invasive 2 100 0 0 15 Luminal B-like(HER2 negative)
#21 C21d Ductal 2 90 0 0 10 Luminal B-like(HER2 negative)
#22 C22i 78 1/0/0 I Invasive 2 100 5 1 20 Luminal B-like(HER2 negative)
#23 C23i 55 1/0/0 I Invasive 3 100 0 0 25 Luminal B-like(HER2 negative)
#24 C24d 33 1/0/0 I Ductal 2 100 60 0 5 Luminal A-like
#25 C25L 58 1/1/0 IIA LNs meta 2 50 0 0 20 Luminal B-like(HER2 negative)
#26 C26i 58 1/1/0 IIA Invasive 3 0 0 1 15 Triple negative
#26 C26L LNs meta 3 0 0 0 15 Triple negative
#27 C27i 64 2/0/0 IIA Invasive 3 0 0 0 10 Triple negative
#28 C28i 35 2/0/0 IIA Invasive 2 0 0 0 1 Triple negative
#28 C28d Ductal 2 0 0 0 1 Triple negative
#29 C29i 61 1/1/0 IIA Invasive 2 0 0 0 3 Triple negative
#29 C29L LNs meta 2 0 0 0 30 Triple negative
#30 C30i 59 1/0/0 I Invasive 3 0 0 0 18 Triple negative
#30 C30d Ductal 3 0 0 0 13 Triple negative
#31 D1 79 0 DCIS 1 100 15 0 1 Luminal B-like(HER2 negative)
#32 D2 51 0 DCIS 2 100 10 0 2 Luminal B-like(HER2 negative)
#33 D3 40 0 DCIS 2 60 60 1 4 Luminal A-like
#34 D4 52 0 DCIS 2 0 0 3 10 HER2 positive(non-luminal)
#35 D5 46 0 DCIS 2 90 90 0 13 Luminal A-like
#36 D6-m 49 0 DCIS 1 95 70 2 12 Luminal A-like
#36 D6-s DCIS 1 99 30 2 10 Luminal A-like
#37 D7 53 0 DCIS 3 40 10 0 20 Luminal B-like(HER2 negative)
#38 D8 52 0 DCIS 2 90 95 2 7 Luminal A-like
#13 D9-w1 57 0 DCIS 1 100 50 1 7 Luminal A-like
#39 D10 64 0 DCIS 2 80 20 0 2 Luminal A-like
#40 D11 51 0 DCIS 1 90 60 1 1 Luminal A-like
#41 D12 44 0 DCIS 1 99 95 1 10 Luminal A-like
#41 P12 0 DCIS 1 80 80 0 3 Luminal A-like
#42 D13 63 0 DCIS 2 0 0 3 25 HER2 positive(non-luminal)
#43 D14 57 0 DCIS 3 0 0 3 10 HER2 positive(non-luminal)
#17 D15-w2 84 0 DCIS 2 0 0 3 10 HER2 positive(non-luminal)
#44 D16 68 0 DCIS 1 100 0 0 3 Luminal B-like(HER2 negative)
#45 D17 61 0 DCIS 2 100 0 3 10 Luminal B-like(HER2 positive)
#46 D18 52 0 DCIS 1 5 0 3 3 Luminal B-like(HER2 positive)
#47 D19 35 0 DCIS 1 100 0 1 5 Luminal B-like(HER2 negative)
#48 D20 56 0 DCIS 2 5 0 3 10 Luminal B-like(HER2 positive)
#49 D21 59 0 DCIS 2 100 30 0 5 Luminal A-like
#50 D22 49 0 DCIS 2 100 80 0 5 Luminal A-like
≧2probes ≧3probes ≧4probes2828genes ≧5probes
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w1 D9-w1 D6-m D6-s C15d C15i D12 P12 C22i D11 D16 D22 D1 D19 D18 D21 C20d C20i D17
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TMC1 9q 9q 3.57E-14 0.03 -0.1 0.09 0.14 0 0.45 0.5 0.47 0.63 0.28 0.73 0.28 0.22 0.08 0.19 0.16 0.05 0.21 0.12 0.33 0.24 0.12 0.23 -0.2 0.11 0.4 0.39 0.49 0.09 0.07 0.04 0.16 0.07 0.52 0.08 0.18 -0.1 0.34 0.38 -0.1 0.42 0.6 0.03 0.31 -0.1 -0.2 0 -0.1 0.16 0.19 -0.3 -0.3 -0.3 -0.1 -0.4 0.01 0.04 -0.2 0 -0.4 0.01 -0.2 -0.1 0.22 0 0 -0.3 -0.2 0 0.05 -0.4 -0.2 -0.2 0.06 -0.3 -0.4 0.01 0.02 -0.5 -0.6 0.01
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MED19 11q 11q 6.41E-13 0.54 0.21 0.18 0.08 0.05 -0.2 0.18 0.59 0.84 0.22 1.01 0.34 0.65 0.05 0.43 0.13 0.12 0.3 0.42 0.57 0.22 0.23 0.54 -0.2 0.32 0.91 1.2 1.34 0.64 0.6 0.58 0.37 1.13 0.65 0.77 1.14 -0.3 0.42 0.66 0.14 0.89 1.08 0.21 0.52 -0.5 -0.3 0.06 -0.2 0 -0.1 -0.4 0.01 0.13 -0.1 -0.9 -0.1 -0.1 0.11 -0.2 -0.3 -0.1 -0.1 -0.4 -0.2 -0.1 -0.1 -0.5 -0.2 0 0.03 -0.2 -0.4 -0.2 -0.1 -0.2 -1.6 -0.5 -0.5 -1.2 -1.1 -0.3




OK (A) 0.23 0.08 0.17 0.21 0.12 0.13 0.07 0.12 0.44 0.6 0.09 0.17 -0.1 0.39 0.46 0.65 0.62 0.25 0.68 1.06 0.63 0.56 0.41 0.11 0.64 0.73 1.01 1.19 0.72 0.61 0.47 0.66 1.15 1.41 1.16 1.28 0.05 0.55 0.69 0.15 0.85 0.92 0.21 0.59 -0.4 -0.1 0.28 0.3 -0.3 -0.1 -0.1 0.11 0 0.22 -0.3 -0.2 -0.3 -0.2 0.07 0.1 0.14 0.1 0 0.22 -0.2 0.03 -0.2 0.22 0.02 0.39 0.2 -0.4 0 -0.5 -0.4 -1.2 -0.2 -0.2 -1.1 -1 -0.3
USP30 12q 12q 8.83E-13 -0.4 -0.2 -0.2 0.04 0.04 0 0.21 -0.5 -0.2 -0.1 -1.1 -0.3 -0.6 -0.2 -0.2 -0.3 -0.2 -0.1 -0.5 -0.9 -0.1 -0.1 0 0.3 0.14 -0.4 -0.6 -0.7 -0.2 -0.1 -0.3 -0.2 -0.3 -0.3 -0.7 -0.5 0.23 0.11 0.21 -0.3 -0.6 -0.4 -0.4 -0.6 0.02 -0.1 -0.3 -0.1 -0.4 -0.4 0.6 0.4 0.23 -0.2 0.35 0.45 0.32 0.51 0.08 0.17 0.11 -0.2 -0.1 -0.1 0.18 0.1 0.61 0.51 -0.1 0 0.09 0.43 0.26 0 0.15 0.06 0.13 -0.1 0.12 0.29 0.68




OK (A) 0.81 0.44 -0.2 0.07 0.53 0.59 0.31 0.82 1.1 0.38 0.82 0.22 0.02 0.35 0.61 0.98 0.65 0.5 0.72 0.9 0.54 0.49 0.43 0.41 0.32 0.39 0.72 0.59 0.33 0.14 0.29 0.44 0.5 1.95 0.92 1.18 0.82 1.46 1.17 -0.1 0.37 0.4 0.11 0.85 0.17 0.21 0.22 0.35 0.59 0.63 -0.2 0 0.04 0.21 0.24 -0.1 0.03 0.06 0.02 0.02 0.09 -0.5 -0.4 0.26 0.01 0.21 0.38 0.33 0.07 0.28 0.77 0.03 0.21 -0.5 -0.4 -0.6 -0.1 -0.3 -0.4 -0.7 -0.1
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RARB 3p 3p TSG 1.14E-11 0.2 -0.1 -0.2 0.2 0.07 -0.1 0.01 0.5 0.34 0.61 0.66 -0.2 0.04 -0.1 0.27 0.24 0.13 0.06 0.31 0.56 0.37 0.17 0.31 0 0.44 0.27 0.69 0.75 0.38 0.29 0.24 0.3 0.29 0.51 0.14 0.1 0.05 0.02 0.32 0 0.4 0.28 0.08 0.48 -0.3 -0.1 -0.5 -0.1 0.16 0.18 -0.2 -0.2 -0.1 -0.3 -0.5 0.06 -0.3 -0.3 -0.3 -0.2 0 -0.4 -0.4 0 0.23 0 -0.1 0 -0.2 0 -0.2 0 0 -0.2 -0.3 -1.1 -0.2 -0.2 -0.5 -0.5 -0.1
GJC1 17q 17q 1.37E-11 0.16 -0.2 -0.1 -0.3 -0.2 0.09 0.03 -1.8 -1.6 -0.5 -0.5 -0.3 -0.1 -0.3 0 -0.3 -0.2 -0.6 -0.5 -0.5 -0.9 -0.3 -0.5 -0.4 0.37 -0.7 -1.1 -1 0.08 -0.5 -0.4 -0.2 -0.7 -1 -1.8 -0.9 -0.7 -0.4 -0.6 -0.2 -1.3 -2.5 -0.4 -0.7 0.17 0.28 -0.5 -0.5 0.05 -0.1 0.54 0.42 0.27 -0.5 0.09 -0.6 -0.3 0 0.32 0.56 0.2 -0.2 0.38 0.23 -0.1 -0.2 0.18 0.47 0.13 0.24 -0.3 0.17 0 0.56 0.27 0.51 0.36 0.64 1.27 1.67 0.44




X(A), OK(B) 0.19 0.15 -0.2 -0.1 0.02 -0.1 0.3 0.44 0.58 0.45 0.09 0 -0.2 0.26 0.5 0.87 0.84 0.57 0.5 0.71 0.02 0.47 0.61 0.27 0.02 0.39 0.39 0.64 0.32 0.36 0.45 0.48 0.36 1 0.41 0.93 0.08 0.18 -0.3 0.27 -0.1 0.49 0 0.55 0.38 0.32 0.15 0.28 0.26 0.31 -0.1 0 -0.3 0.05 -0.4 0 0 -0.1 -0.4 -0.2 -0.3 -0.7 -0.4 -0.1 0.11 -0.2 0.12 0.21 0.32 0.23 0.09 0 0.18 0.01 0.01 -0.5 -0.1 0.13 -0.6 -0.3 -0.1
AB231754 1.53E-11 -0.1 -0.3 -0.6 0 -0.1 -0.2 0.29 -0.6 -0.3 0 0.19 -0.4 -0.3 0.68 -0.4 -0.7 -0.4 -0.8 -0.9 -0.7 -0.9 -0.2 -0.2 -0.2 0.23 -0.7 -0.5 -0.4 -0.3 -0.2 -0.5 -0.3 -0.5 -0.6 -0.6 -0.3 0.01 0.02 -1.5 0.17 -1 -1.1 -0.9 -0.9 -0.1 -0.6 -0.4 -0.2 -0.4 -0.4 0.43 0.38 0.56 -0.2 0.6 0.14 0.13 0.1 0.15 -0.1 -0.1 0.12 0.27 0.14 0.19 0.07 -0.1 -0.1 -0.1 0.05 0 -0.1 -0.3 0.08 0.41 0.08 0.11 -0.1 0.23 0.25 -0.3
SFRS6 20q 20q 1.71E-11 0.68 0.28 0.15 0.19 0.37 0.26 0.11 1.21 0.99 0.62 1.79 0.56 0.86 0.23 0.17 0.33 0.42 0.53 0.59 0.74 0.24 -0.1 0.05 0 0.43 0.36 0.84 1.04 0.4 0.37 0.55 0.49 0.51 0.72 0.48 0.71 -0.1 0.09 -0.2 -0.1 0.58 0.01 0.34 0.3 -0.3 -0.1 0.04 0 0 0 -0.1 -0.1 0.44 0.07 -0.6 -0.4 -0.2 -0.4 -0.1 0 0.05 -0.6 -1 -0.2 0 0.12 -0.3 -0.2 0 0 -0.6 -0.2 0.09 -0.7 -0.4 -1.1 -0.1 -0.2 -0.6 -0.8 0
SPSB4 3q 3q 1.89E-11 0.14 -0.6 0.1 -0.2 0.13 -0.7 0.12 -0.1 -0.1 -0.8 -0.5 0 -0.1 -0.3 -0.1 -0.4 0 -0.4 -0.5 -0.6 -0.2 -0.3 -0.2 0.1 -0.5 -0.4 -1.7 -0.7 -0.5 -0.6 -0.4 -0.5 -0.5 0.45 -0.4 -0.1 0.2 -0.4 -0.6 -0.3 -0.1 -0.2 -0.1 -0.3 0.33 0.09 0.13 0.15 -1.4 -1.9 0.29 0.26 0.29 -0.4 0.63 0.13 0.27 0.38 0.6 0.82 0.32 0.34 0.82 0.25 0.05 -0.3 -0.2 0.01 0.26 0.2 0.52 -0.2 -0.1 0 0.12 0.01 0.42 0.09 -0.2 0.04 0.3
TP53I11 11p 11p 2.11E-11 0.45 0.22 0 0.08 0.26 -0.1 0.44 0.74 0.54 0.46 1.31 0.03 0.16 -0.5 0.55 0.28 0.3 0.26 0.43 0.72 0.16 0.2 0.29 -0.3 0.3 0.66 1.06 1.02 0.29 0.4 0.5 0.29 0.57 0.52 0.67 0.76 0.01 0.62 0.32 0.22 1.38 1.2 0.1 0.24 -0.6 -0.2 -0.2 -0.2 -0.5 -0.5 -0.5 -0.2 -0.1 -0.1 -0.6 0.07 0.24 0 0.1 -0.1 -0.1 -0.3 -0.5 -0.1 -0.1 0 -0.6 -0.5 -0.2 -0.1 -0.2 -0.2 0.03 0.1 -0.2 -1.4 -0.2 -0.3 -0.8 -0.8 -0.3
SYCP1 1p 1p 2.38E-11 0.56 0.29 0 0.05 0.13 0.43 0.09 0.73 1.03 0.39 1.21 -0.3 -0.2 -0.2 0 -0.1 0 0.55 0.4 0.36 -0.1 0.13 -0.1 0.11 -0.1 -0.2 0.67 0.8 0.18 0.26 0.66 0.35 0 0.18 0.27 0.61 -0.2 0.17 -0.1 0.27 0.01 -0.1 -0.1 0.77 -0.2 0.11 -0.1 -0.2 0.1 0.14 -0.3 -0.2 -0.2 0.07 -0.4 0 0 -0.3 -0.1 -0.2 -0.1 -0.1 -0.3 0.29 -0.1 0 -0.1 -0.3 -0.1 -0.2 -0.2 -0.1 -0.2 -0.2 -0.1 -0.5 -0.1 0.05 -0.2 -0.5 -0.3
GBP6 1p 1p 2.53E-11 0.27 -0.1 0.24 0.14 0.05 0.04 0 0.49 0.71 0.32 0.05 0.05 0.23 -0.1 0.15 0.25 0.01 0.6 0.57 0.88 0.53 0 0.24 -0.4 -0.1 0.99 1.43 1.33 0.64 0.28 0.19 0.21 0.51 0.53 1.24 1.1 -0.7 0.21 0.45 0.02 0.3 -0.1 -0.1 0.83 -0.5 -0.3 -0.2 -0.3 -0.5 -0.3 -0.9 -0.8 -0.4 0 -1 0.11 -0.1 -0.8 0.24 0.35 0.18 0.51 0.43 -0.3 -0.1 0 -0.6 -0.5 -0.5 -0.4 -0.5 -0.8 -0.5 -0.5 -0.7 -0.9 -0.4 -0.4 -1.2 -1 -0.5
U2AF1 21q 21q 3.67E-11 0.13 0.2 0.07 -0.1 -0.1 -0.1 -0.2 0.81 0.17 0.14 0.79 -0.3 0.06 0 0.06 0.15 0.3 0.15 0 0.48 0.09 0.26 0.28 0.07 0.2 0.78 0.55 0.62 0.22 0.5 0.16 0.57 0.38 1.46 0.36 0.69 0.37 0.54 0.6 0.23 0.78 0.69 0 0.17 -0.1 -0.2 0.26 0.31 -0.1 -0.1 -0.2 -0.2 0.05 0.16 -0.3 -0.2 -0.3 0.01 -0.2 0 -0.3 -0.3 -0.7 -0.6 -0.4 -0.4 -0.1 0 -0.2 -0.3 -0.1 -0.2 -0.1 0.06 -0.5 -0.6 -0.1 -0.4 -0.2 0.15 -0.2




OK(A) 0.51 0.29 -0.2 0.25 0.51 0.37 0.2 0.54 0.55 -0.1 1.55 0.34 0.04 -0.1 0.19 0.31 0.17 0.66 0.85 0.4 0.45 0.28 0.33 0 0.06 0.46 0.55 0.75 0.37 0.5 0.26 0.4 0.08 0.34 0.35 0.3 0.13 0.44 0.87 0.07 0.24 0.16 0.17 0.28 -0.2 -0.1 -0.4 -0.1 -0.1 -0.2 -0.3 -0.1 0 0.33 -0.2 0.02 -0.5 -0.1 -0.2 -0.2 0.26 -1.1 -0.4 -0.3 -0.1 0.14 -0.3 -0.1 0.01 -0.1 -0.2 -0.3 -0.2 -0.1 -0.4 -1 0 0 -0.5 -0.4 -0.1
AL832136 3.93E-11 0.21 0.21 0.07 0 0.08 -0.4 0.16 0.3 0.34 0.09 0.87 0.06 0.37 -0.4 0.2 0.22 0.21 0.22 0.48 0.74 0.73 0.59 0.46 -0.4 0.38 0.56 1.12 1.12 0.24 0.33 0.3 0.37 0.5 0.71 1.19 1.04 -1 0.35 0.8 -0.4 1.11 0.83 0.06 0.57 -0.4 -0.4 -0.4 -0.7 0.19 0.3 -0.5 -0.4 -0.1 -0.6 -1 0.13 -0.3 0 0.21 0.21 -0.3 -0.1 -0.3 0 0.21 -0.1 -0.4 -0.4 -0.3 0 -0.7 -0.3 -0.3 -0.4 -0.6 -2.2 -0.1 -0.3 -1 -1 -0.2
AKAP8 19p 19p 4.09E-11 -0.3 0 -0.3 -0.1 0.03 -0.5 0.07 0.22 -0.5 0.07 -0.6 0.11 0.05 -0.2 0 -0.3 -0.5 -0.4 -0.4 -0.4 -0.1 -0.2 -0.3 -0.1 -0.2 -0.2 -0.9 -0.4 -0.1 0 -0.1 0.05 -0.6 0.07 -0.5 -0.3 0.48 0.41 -0.3 -0.2 -1.3 -0.5 -0.3 -0.6 -0.1 -0.3 0 -0.1 -1 -1.2 0.56 0.54 0.16 0.23 0.35 0.21 0.12 0.09 0.05 0.37 0 0.16 0.17 0 0.38 0.42 0.3 0.08 0.25 0.2 0.19 0.01 -0.1 0.05 0.23 0.24 0.15 0 0.12 0.25 1.36
R3HCC1 8p 8p 4.47E-11concordant (A, (B)) 0.18 0.01 0.25 0 -0.1 -0.3 -0.3 0.02 -0.4 -0.1 0.12 -0.9 -0.9 0.14 -0.2 -0.5 -0.3 -0.3 -0.8 -1.4 -1.1 -0.3 -0.8 0.56 -0.6 -0.5 -0.7 -1.2 0 0.14 -0.4 -0.3 -1.2 0.1 -1 -0.5 -1 -2.1 -0.2 0 0.08 0.65 -0.8 -0.2 0.5 0.42 -0.8 -0.8 -1.1 -1.6 1.01 1.08 1.28 -0.3 0.44 0.11 -0.3 0.09 0.11 0.31 -0.2 0.07 -0.1 0.35 0.15 -0.1 0.13 0.68 0.37 0.45 -0.2 0.1 0.26 1.07 0.8 0.53 -0.1 0.72 0.35 0.57 -0.2




OK(A) -0.1 0.33 -0.7 0.01 0.05 0.16 -0.1 0.2 0.08 -0.1 0.29 -0.1 -0.1 0.02 0.73 0.66 0.72 0.47 0.58 0.64 0.1 0.28 0.1 0 -0.1 0.08 0.97 0.83 0.47 0.07 0.27 0.33 0.32 1.53 0.55 0.92 0.05 -0.2 0.22 0.12 -0.4 -0.4 -0.2 0.64 -0.2 0.07 0.26 0.05 -0.1 -0.2 -0.3 0.02 -0.3 0.15 -0.5 0 0.17 -0.2 0 -0.1 0 -0.7 -0.3 0.14 0 0 -0.2 -0.4 0 0.1 0 -0.3 -0.2 -0.8 -0.7 -0.9 -0.2 -0.2 -1.1 -1.1 -0.6




OK(A) -0.5 0.14 0.12 0.02 0.05 0.41 0.17 0.39 0.59 0.25 -0.3 0.39 0.08 0.66 0.7 0.89 0.81 0.77 0.71 0.48 0.34 0.38 0.4 0.21 0.29 0.24 0.36 0.43 0 -0.1 0.06 0.01 0.24 1.12 0.34 0.53 0.02 0.46 0.01 0.02 0.56 0.72 0.02 0.75 0.18 0.23 0.38 0.24 0.37 0.49 0.05 0.17 0 -0.1 -0.4 0.23 0.01 0 -0.2 -0.1 -0.3 -0.3 -0.6 -0.2 0.08 0.26 0.03 0.1 0.24 0.31 0.1 -0.1 -0.2 -0.4 -0.2 -0.4 0.2 0.09 -0.4 -0.5 0.03




OK(B) -0.1 0 -0.1 -0.2 -0.1 0.13 0.09 0.39 1.18 -0.1 1.04 0.21 0 0.14 -0.1 0.04 -0.2 -0.2 -0.2 0.14 -0.2 0.12 -0.3 -0.1 0.16 0.38 0.53 0.9 0.52 0.16 0.34 0.27 1.09 0.75 0.39 0.43 -0.4 0.14 -0.2 0.09 -0.1 -0.3 0.03 0.13 -0.4 -0.6 -0.3 0.12 -0.4 -0.5 -0.3 -0.3 -0.1 0 -0.6 -0.4 -0.3 -0.7 -0.4 -0.5 -0.4 -0.4 -0.6 -0.4 0.05 -0.5 -0.4 -0.2 -0.2 -0.3 -0.3 -0.4 -0.3 -0.3 -0.5 -0.7 0.11 0.05 -0.2 -0.1 -0.2
ZNF100 19p 19p 7.83E-11 0.42 0.16 0.12 -0.1 0.09 -0.2 0.02 0.61 0.83 0.44 1.69 0 -0.1 -0.1 0.02 0.14 0.27 0.25 0.32 0.4 0.06 0.22 0.24 -0.1 -0.1 0.46 0.4 0.4 0.14 0.21 0.3 0.2 0.51 0.52 0.4 0.68 -0.1 0.09 0 -0.1 1.38 1.71 -0.1 0.08 -0.4 -0.2 -0.3 -0.1 0 -0.2 -0.3 -0.3 -0.1 -0.1 -0.7 0.03 0 0.25 -0.2 0.04 -0.2 -0.2 -0.4 -0.1 -0.1 0.07 -0.3 -0.1 0.08 0 -0.1 -0.3 -0.4 -0.5 -0.2 -1 -0.3 -0.5 -0.9 -0.7 -0.4
MORC1 3q 3q 1.01E-10 -0.1 -0.3 -0.5 -0.1 0.01 -0.4 0.55 0.11 -0.3 0.18 0.71 0 -0.1 0.05 0.36 0 0.18 0.1 0.12 0.28 0.36 0.19 0.33 0 0.28 0.19 0.18 0.56 0.2 0.11 0.06 -0.1 0.76 0.63 0.59 0.46 0.08 0.43 0.56 -0.2 0.16 0.17 0.18 0.25 -0.4 -0.1 0.1 0.01 0.16 0.16 -0.5 -0.2 -0.4 -0.2 -0.5 -0.3 -0.3 -0.1 -0.2 -0.3 -0.7 -0.5 -0.9 -0.8 -0.1 -0.3 -0.3 -0.1 -0.1 -0.1 -0.1 -0.2 0 -0.2 -0.3 -0.6 0.02 0 -0.5 -0.6 0
LOC728392 17p 17p 1.01E-10 -0.2 -0.3 -0.7 0.09 0.23 0.1 0.36 -0.7 -0.3 -0.3 0.03 -0.2 -0.1 -1.3 -0.3 -0.1 -0.3 -0.6 -0.9 -0.5 -1 -0.8 -1.5 -0.4 0.85 -1 -2.2 -1.3 -0.6 -1.3 0.15 -1.1 -1.3 -1.1 -1.1 -1.2 -0.8 0.59 -2.1 -0.9 -1.5 -1.4 -1.7 -1.3 -0.2 0.16 -0.9 -0.6 -0.7 -0.5 0.73 0.48 1.38 -0.7 0.07 0.08 -0.1 -0.1 0.12 0.09 0.27 0.03 0.3 0.44 0 0.22 0.1 0.28 0.09 0.19 -0.2 0 0.02 0.11 0.08 0.05 -0.4 -0.1 1.06 1.84 0.13
ABHD13 13q 13q 1.04E-10 -0.3 0 -0.1 -0.1 -0.2 0.21 0.43 0.35 -0.2 0.02 0 0.1 0.06 0.34 0.49 0.47 0.31 0.07 0.3 1.36 0.52 0.51 0.46 -0.5 0.07 0.27 1.18 1.41 0.63 0.37 0.61 0.6 0.65 0.58 0.34 1.12 -0.2 0.12 0.52 0.36 0.19 0.91 0.23 0.31 -0.3 -0.4 -0.6 -0.5 -0.3 -0.4 -0.7 -0.4 -0.1 0.26 -0.9 -0.4 -0.5 -0.3 -0.2 0.33 0.56 -0.7 0.2 0.32 -0.3 0.07 -0.5 -0.6 -0.4 -0.2 -0.6 -0.6 0.07 -0.5 -0.8 -1.4 -0.5 -0.3 -0.8 -0.6 -0.6
DNAJC8 1p 1p 1.12E-10 0.83 0.47 0.11 0.4 0.26 0.37 0.18 1.24 1.24 1.21 1.39 0.4 -0.1 -0.4 0.48 0.23 0.13 0.37 -0.1 0.79 0.38 0.59 0.27 -0.1 0.26 0.47 0.84 1.4 0.15 0.17 0.68 0.44 1.09 0.49 0.65 1.09 -0.1 0 -0.7 0.46 1.3 1.15 0.09 0.47 -0.3 -0.2 0.33 0.04 -0.1 -0.3 -0.1 -0.2 0.06 0.11 -0.7 -0.1 -0.1 0.01 0.02 0.03 -0.1 -0.3 -0.8 0.04 -0.4 -0.1 -0.5 -0.1 0 -0.2 -0.1 -0.2 -0.2 -0.1 -0.8 -1.9 -0.8 -0.2 -0.3 -0.4 -0.2




OK(A) 0.58 0.22 -0.2 -0.1 0.15 0.13 0.07 0.38 0.84 0.25 1.75 0.25 0.28 -0.1 0.34 0.24 0.18 0.08 0.11 0.56 0.2 0.26 0.09 -0.3 0.22 0.62 0.93 1.21 0.18 -0.1 0.07 0.19 0.36 0.12 0.49 0.61 -0.7 0.26 -0.3 0 1.05 1.1 0.04 0.66 -0.3 -0.1 -0.5 -1 0.11 0.18 -0.1 0.08 0.14 -0.5 -0.6 -0.1 0.05 0.17 0.09 -0.2 -0.2 -0.9 -1 -0.7 -0.3 -0.2 -0.5 -0.4 -0.3 -0.3 -0.2 -0.4 -0.2 -0.5 -0.3 -1.1 -0.1 -0.1 -0.5 -0.5 -0.1




-0.3 -0.4 0.02 -0.1 0.26 -0.2 0.36 -0.1 -0.3 0.07 -0.2 -0.7 -0.7 -0.3 -0.3 0 0.03 -1.1 -1 -1 -0.6 -0.1 -0.7 -0.6 0.05 -0.4 -0.3 -1.2 -0.5 -0.1 -0.5 -0.1 -0.9 -1.1 -1.2 -1.3 0.44 -1.6 -1.7 0.24 -0.9 -1.4 -0.2 -1.3 -0.2 -0.2 -0.8 -0.3 0.11 0.08 1.02 1.11 1.25 -0.2 1.21 -0.2 0.39 0.38 0.38 0.44 0.12 0.35 0.2 0.34 0.03 -0.1 -0.1 0.12 -0.2 0.03 0.95 0.26 0 -0.8 0.94 0.44 -0.3 0.43 0.37 0.48 -0.6
DDX20 1p 1p 1.23E-10 0.62 0.56 0.41 0.32 0.1 0.28 0.11 0.97 1.15 0.53 0.57 0 -0.1 0.55 0.2 0.04 0.06 -0.3 -0.1 0.49 -0.1 0.32 0.27 -0.1 0.19 0.09 0.3 0.9 0.43 0.62 0.42 0.49 0.48 0.24 0.61 0.62 -0.2 0.22 -0.1 0.1 0.49 0.95 0.09 0.25 -0.1 -0.2 -0.1 -0.1 -0.3 -0.1 -0.3 0 0.17 0.1 -0.5 -0.1 -0.2 0 0.08 0.1 0.01 0.15 -0.1 0.39 -0.1 0.06 -0.4 -0.3 0.03 0 -0.3 0 0.3 -0.4 -0.5 -0.3 -0.2 -0.3 -0.4 -0.3 -0.1
POLE4 2p 2p 1.41E-10 0.46 0.25 0.24 0.23 -0.1 -0.2 0.57 0.27 -0.2 -0.3 -0.3 -0.1 0 -0.4 -0.2 -0.1 -0.2 -0.5 -0.2 -0.1 0.15 0.01 -0.1 0.03 -0.1 0.3 -0.3 -0.5 -0.1 -0.4 0 -0.2 -0.3 0.13 -0.2 0 0.36 0.34 -0.8 0.07 -1.1 -0.2 0.17 -0.7 0.12 0.12 -0.3 0.06 -0.1 -0.2 0.65 0.49 0.2 0.3 0.5 0.19 0.68 0.33 0.8 1.12 0.52 1.12 1.16 0.53 0.09 0.24 0.28 0.37 0 0.07 0.2 0.17 0.07 0.51 0.19 0.41 -0.2 -0.1 0.23 0.43 0.15
OR13A1 10q 10q 1.50E-10 0.05 0.05 0 -0.1 -0.1 0.04 -0.2 0.51 0.51 0.38 1.81 -0.4 -0.5 0.31 -0.2 -0.1 -0.2 -0.3 -0.1 0.17 -0.1 0.44 0.28 0.17 -0.3 0.32 0.05 0.05 -0.2 0.07 0.12 -0.1 0.24 0.71 0.38 0.83 0.41 0.23 -0.2 0.26 0 0.56 -0.2 0.68 0.34 0.72 -0.1 0 0.36 0.29 -0.5 -0.1 -0.3 0.11 -0.5 -0.1 -0.1 -0.2 -0.3 -0.5 -0.2 -0.1 -0.6 -0.2 -0.1 0.12 -0.6 -0.2 -0.3 -0.4 -0.2 -0.5 -0.2 -0.2 -0.2 0.15 -0.1 -0.5 -1.1 -0.7 -0.7
KCNJ14 19q 19q 1.50E-10 -0.3 0.07 0.45 0.3 0.06 -0.7 -0.3 -0.4 -0.5 -0.4 -0.5 -0.3 -0.6 -0.6 -0.6 -0.3 0 -0.2 0.45 -0.4 -0.1 -0.7 -0.7 -0.1 0.46 -0.5 -1.9 -1.5 -0.7 -1 -0.9 -0.9 -0.4 -1 -0.9 -0.9 -0.4 -0.7 -1.2 -0.5 -0.8 -0.2 0.29 -0.6 0.1 -0.1 -0.4 -0.2 -0.7 -0.8 0.6 0.34 0.23 -0.5 0 0.03 0.15 0 0.09 0.54 0.07 -0.2 0.61 0.21 0.4 0.04 -0.3 0.07 0.17 0.26 0.01 -0.3 0 0.62 0.42 -1 -0.7 0.21 1.05 1.19 0.22
FMO2 1q 1q 1.56E-10concordant (A, B) OK(A) 0.79 0.48 0 0.15 0.12 0.28 0.08 0.77 0.42 0.82 1.46 0.27 0.02 0.52 1.27 1.1 1.18 0.86 0.93 1.16 0.99 0.67 0.53 0.35 0.48 0.9 0.83 0.88 0.5 0.45 0.32 0.3 0.62 1.91 1.04 1.15 0.04 0.25 0.33 0.74 0.78 0.53 -0.4 0.69 0.04 0.01 0.26 0.48 0.51 0.42 0.17 0.26 0.37 0.25 -0.4 0 -0.1 0.16 -0.1 -0.1 0 -0.4 -0.4 0.05 0 0.12 0.11 0 0.32 0.55 0.23 0.02 -0.1 0.28 -0.8 0.22 0.43 -0.3 0.31 0.22 0.29
MRPL33 2p 2p 1.57E-10 -0.2 -0.4 -0.1 -0.1 0.03 0 0.67 -0.7 0.02 -0.2 -0.6 0 -0.2 -0.5 0.15 -0.3 0 -0.1 -0.2 -0.5 -1.2 -0.4 -0.3 0 -0.5 -0.3 -0.4 -0.7 -0.3 -0.5 -0.4 -0.2 -0.3 -0.7 -0.5 -0.5 0.46 0.06 -1.3 0 -0.6 -0.1 -0.1 -0.9 -0.3 -0.5 -0.7 -0.4 0.58 0.46 0.42 0.27 0.27 0.07 0.96 -0.2 0.17 0.33 0.28 0.63 0.42 0.4 0.17 -0.1 0.03 -0.2 0.15 0.29 0 0.07 0.51 0.08 -0.2 -0.2 0.26 0.77 0.22 0.24 1.25 1.11 0.21
NMUR2 5q 5q 1.91E-10 -0.2 0 0 0.29 0.51 0 0.3 0.21 0.13 0.14 0.57 -0.4 -0.3 0.36 0.24 0 0.24 0.74 0.79 0.96 0.49 0.54 0.53 0.24 0.47 0.68 1.2 1.01 0.31 0.74 0.38 0.51 0.44 0.78 0.61 0.55 0.39 0.05 -0.2 0.27 0.57 0.51 0 0.37 0.05 0.37 0.31 0.18 0.31 0.49 -0.4 -0.3 -0.2 0 -0.2 -0.1 0.2 0.45 0.05 0 0 0.47 0.06 0.35 0.22 0.16 -0.1 -0.1 -0.1 -0.1 0.07 -0.3 0.07 0.08 -0.2 -0.4 0.03 -0.1 -0.6 -0.6 -0.3
ZNF215 11p 11p 1.97E-10 -0.1 0.02 -0.2 -0.1 -0.1 0.21 -0.1 -0.1 0 0.17 0.55 0.08 -0.1 0.17 0.56 0.22 0.28 0.51 0.58 0.77 0.58 0.55 0.65 0.2 0.55 0.69 1.26 1.13 0.47 0.66 0.74 0.78 0.96 0.34 0.8 0.57 -0.1 0.48 -0.2 0.16 1.23 1.21 0.19 0.59 -0.2 0.07 0.43 -0.1 -0.2 -0.1 -0.6 -0.4 -0.1 -0.3 -0.7 -0.1 -0.2 0.28 -0.3 0.1 -0.3 0.05 0 0.14 0.03 0.04 -0.1 0.02 0 0 0.09 -0.1 0.3 -0.2 -0.3 -0.8 0.12 0 -0.5 -0.5 0.05
ELOVL7 5q 5q 2.03E-10 0.01 0.1 0 -0.1 -0.1 -0.2 0.07 0.49 0.27 0.4 0.7 -0.2 -0.5 -0.3 0.34 -0.1 0.29 -0.1 -0.2 0.28 0.74 0.14 0.02 -0.1 0.02 0.42 0.67 0.76 0.32 0.46 0.1 0.04 0.12 0.31 -0.3 -0.3 -0.3 0.47 -0.3 0.28 0.44 0.44 0.27 0.07 -0.1 -0.3 0.18 -0.1 0.18 0.08 -0.2 -0.1 -0.2 -0.2 -0.7 0.02 -0.2 -0.3 0.03 -0.3 0.02 -0.1 -0.2 0.26 -0.2 -0.1 -0.4 -0.3 -0.1 -0.2 -0.4 -0.2 -0.2 -0.3 -0.2 -0.5 -0.3 -0.2 -0.4 -0.3 0.13




0.74 0.03 0.15 0.06 0.11 -0.1 -0.2 1.35 0.75 0.53 0.98 0.22 0 0.16 0.12 0.25 -0.1 -0.1 -0.2 0.35 0.04 0.08 0.1 0.04 0.19 0.81 1.17 1.24 0.5 0.19 0.41 0.33 1.14 0.76 0.19 0.6 -0.4 0.49 0.24 -0.2 0.27 0.45 0.12 -0.1 -0.6 -0.8 0.25 0.26 -0.2 -0.2 -0.5 -0.1 0.24 0 -0.5 -0.2 -0.2 -0.1 -0.5 -0.5 -0.3 -0.4 -0.6 0.14 -0.2 -0.2 -0.3 0 -0.3 -0.2 -0.1 -0.6 -0.3 -0.5 -0.3 -0.6 -0.4 0 -0.5 -0.5 -0.3




















w1 D9-w1 D6-m D6-s C15d C15i D12 P12 C22i D11 D16 D22 D1 D19 D18 D21 C20d C20i D17
APC 5q22.2 5q 5q TSG 4.43E-10 discordant OK 0.82 0.5 0.25 0.18 0 0.28 0.32 0.7 0.84 0.53 0.24 -0.3 -0.5 -0.2 0.05 0.08 0.17 0.02 0.11 0.56 0.1 0 0 -0.3 -0.2 0.3 0.58 0.76 0 0.12 0.24 0.03 0.02 0.56 0.3 0.24 0.49 0.63 0.38 0.14 0.34 0.75 0.07 0.37 -0.3 -0.1 -0.2 -0.1 0 0.1 -0.3 -0.4 -0.3 -0.1 -0.2 -0.1 0.11 0.01 0.14 0.03 -0.2 0.08 -0.1 0.29 0 0.21 -0.3 -0.4 -0.2 -0.2 0.01 -0.3 -0.4 -0.1 -0.5 -0.2 -0.1 -0.2 -0.5 -0.5 -0.2
PHF6 Xq26 Xq Xq homeo 5.80E-09 concordant 0.06 -0.3 0 0.09 0.12 0.04 0.12 -0.1 0.44 0 0.37 0.4 0.55 0.1 0.3 0.22 0.34 0.06 0.4 0.66 0.37 0.39 0.22 -0.1 0.38 0.52 0.84 1.09 0.12 0.3 0.45 0.65 0.49 0.18 0.66 0.96 -0.2 0.73 0.76 -0.1 0.92 1.16 -0.1 0.44 -0.3 0 -0.5 -0.5 0.06 0.22 -0.3 -0.2 0.04 -0.1 -0.5 0 -0.3 0.19 -0.1 0.28 0.02 0.27 0 0.12 0.12 0 -0.1 -0.1 0 -0.1 -0.1 0 0.14 -0.2 -0.1 -0.2 -0.3 -0.1 -0.2 -0.4 -0.1
GATA3 10p15 10p 10p P 3.72E-08 concordant OK 0.19 -0.1 -0.5 -0.2 0.02 0.01 0.2 -0.3 0.23 0.1 1.03 0.13 0.28 0 0.57 0.64 0.17 0.32 0.25 0.35 0.29 0.25 0.34 -0.3 0.04 0.39 0.65 0.62 0.3 0.39 0.25 0.06 0.32 0.59 0.78 1 0.17 0.34 -0.4 0.46 1.39 1.41 0.29 0.1 -0.1 -0.2 -0.1 0.01 -0.1 -0.2 -0.1 -0.5 -0.2 0.31 -0.2 -0.2 0.12 0.01 -0.2 -0.2 -0.4 -0.4 -0.2 -0.2 -0.3 0 -0.2 0 0 0.01 -0.1 0.03 -0.2 0.23 -0.2 0.52 -0.1 -0.2 -1.1 -0.9 -0.3
TP53 17p13.1 17p 17p TSG 4.74E-08 concordant OK -0.4 -0.3 -0.4 -0.3 -0.1 0.05 0 0.11 -0.2 -0.4 0.34 -0.1 -0.3 -0.3 -0.1 -0.1 -0.1 -0.3 -1 -0.4 -0.2 -0.3 -0.4 0.05 0.24 -0.7 -0.3 -1 -0.4 -0.5 -0.3 0.09 -0.7 0.13 -0.2 -0.4 -0.3 0.64 0.27 0.06 -1.1 0.03 -0.8 -1.4 -0.4 -0.6 -0.7 -0.7 -1 -1.2 0.31 0.55 0.49 -0.2 0.11 -0.2 -0.1 0.37 -0.1 0.32 -0.2 0.56 0.53 0.06 0 0.34 0.37 0.37 0.2 0.35 0.17 -0.1 0.18 0.22 0.11 -0.3 0.07 -0.4 -0.1 -0.3 0
ATRX Xq21.1 Xq Xq TSG 7.04E-08 discordant X -0.2 -0.1 0.02 -0.4 -0.1 -0.1 -0.5 -0.1 0.62 -0.2 -1.2 0.39 0.37 -0.4 -0.5 -0.1 -0.5 0 -0.7 -0.2 0 -0.1 -0.2 0 -0.4 -0.4 -0.9 -0.2 0.3 -0.7 -0.7 -0.5 -0.4 0 0.15 -0.2 -0.8 -0.5 -0.8 -0.5 -1.6 -1.5 -0.5 0.14 0.13 0.24 -1 -1.3 0.14 0.16 0.34 0.11 0 -0.2 0.35 -0.2 0.07 0.21 0.2 0.55 -0.3 0.09 -0.1 0.04 0.33 -0.1 0 0.37 -0.2 0.1 0.34 0.03 -0.3 -0.5 0.19 -0.5 0.1 0.24 0.64 0.2 0.38
ATR 3q23 3q 3q TSG 1.95E-07 discordant X 0.48 0.23 0.11 0.3 0.21 0.14 0.08 0.28 0.32 0.29 -0.2 0.06 -0.1 0 0.08 0.07 0 0 0.42 0.23 0.09 0.11 0.09 -0.1 -0.1 0 0.17 0.48 0.28 0.27 0.11 0.1 0.54 0.5 0.26 0.33 0.31 0.53 0.06 0.08 -0.3 0.17 -0.1 0.23 -0.1 -0.1 0.11 0.07 0.01 0.1 -0.2 -0.1 -0.1 -0.1 -0.1 0.07 -0.1 -0.1 0.27 0.31 0.41 0.18 0.03 0.39 0.08 0.13 -0.1 -0.3 -0.2 -0.1 -0.1 -0.1 -0.1 -0.2 -0.1 -0.4 0 0 -0.3 -0.3 -0.2
ASXL1 20q11 20q 20q TSG 3.97E-07 discordant X 0.68 0.24 0.05 -0.2 -0.2 0.18 0.35 1 0.74 0.17 1.38 0.04 0.31 -0.4 0.27 0.25 0.1 0.35 0.18 0.26 0.14 0 -0.2 -0.1 -0.5 0.47 0.56 0.57 0.36 0.11 0.03 0.27 0.35 0.53 0.33 0.55 0.23 0.29 0.81 0.17 0.65 0.88 0.17 0.24 -0.1 0 0.14 0 -0.4 -0.4 -0.5 -0.1 0.01 0.11 0 0.39 0.29 0.16 0.04 0.1 0 -0.4 -0.8 -0.1 0.08 0.16 -0.3 -0.3 -0.1 0 0 -0.4 -0.1 -0.4 -0.2 -0.4 -0.1 0.05 -0.1 -0.1 -0.2
SMARCA4 19p13.3 19p 19p TSG 6.83E-07 -0.1 -0.1 -0.3 -0.2 0.14 -0.1 -0.1 -0.5 -0.5 0.14 -0.5 0 0.17 -0.1 -0.3 -0.4 0.15 0.17 0.03 -0.7 0.39 0 -0.3 0.32 0.18 0 -0.8 -0.6 -0.4 -0.1 0 -0.4 -0.6 -0.3 0.71 0.8 0 0 0.01 0.16 -0.1 -0.7 0.07 -0.9 0.15 -0.1 0 -0.2 -1.3 -1.7 0.67 0.7 0.4 0.01 0.32 -0.2 -0.1 -0.3 0.3 0.22 -0.2 0 0.09 0.28 -0.5 -0.1 0.36 0.36 0.37 0.27 0.09 0.22 -0.2 0.75 0.28 -0.4 0.15 0.31 0.34 0.26 0.32
CDKN2A 9p21 9p 9p TSG 1.20E-06 discordant OK -0.1 -0.2 -0.3 0.05 0 0.09 0 0.1 0.42 -0.2 0.57 -0.6 -1.4 0.3 -0.1 -0.2 0 -0.1 0.45 0.38 0.32 0.05 0.23 -0.4 0.01 0.13 0.75 0.73 0.06 0.19 0.46 -0.3 0.33 0.43 0.9 1.1 -1.2 0.63 0.4 -0.2 0.33 0.5 -0.2 0.37 -0.3 0 -0.1 -0.2 -0.2 -0.2 -0.3 -0.2 -0.1 0.2 -0.3 0.28 -0.2 -0.4 -0.3 -0.2 -0.3 -0.3 -0.5 -0.1 -0.6 -0.1 -0.2 -0.4 0.05 -0.1 -0.3 -0.3 -0.2 -0.1 -0.4 -1.1 -0.1 -0.2 -0.6 -0.4 -0.2
TET2 4q24 4q 4q TSG 3.78E-06 concordant OK -0.7 -0.6 -0.1 -0.1 -0.1 -0.9 0 -0.5 -0.7 -0.5 -0.8 -0.6 -0.9 -0.1 0 0.09 0.04 -0.2 -0.2 0.07 -0.2 -0.5 -0.1 -0.4 0.02 0.11 -0.6 -0.2 0.34 -0.1 -0.1 -0.3 0.02 0.21 -0.1 -0.1 -0.3 -0.1 -0.8 -0.1 -0.8 -0.5 -0.1 -0.3 0.01 -0.2 -0.4 -0.3 -0.1 -0.3 -0.1 -0.1 0.04 -0.5 -0.4 -0.2 -0.2 0.2 -0.2 0.19 0.14 0.23 0.47 0.1 0.35 0.02 -0.1 0.07 0.01 0 -0.3 -0.1 -0.2 -0.1 0.02 -0.4 0 0 0.5 0.5 0
STAG2 Xq25 Xq Xq TSG 5.66E-06 discordant X 0.26 -0.4 -0.4 -0.2 -0.1 -0.2 0.39 -0.3 -0.4 0.08 0.18 0.29 0.57 -0.1 0.01 0.06 -0.1 -0.1 -0.1 0.1 -0.2 0.33 0.01 0 -0.2 0.46 0.45 0.68 0.39 0.2 0.12 0.33 0.33 0.14 0.6 0.92 -0.6 0 0.04 0 1.04 0.49 0.03 0.41 -0.1 -0.2 -0.4 -0.5 0 0 0 0 0.29 -0.1 -0.5 -0.2 -0.1 0.35 0.21 0.17 -0.4 0 -0.4 0.07 -0.2 -0.2 -0.1 -0.1 0 -0.1 -0.3 -0.2 -0.3 -0.4 -0.1 -0.8 -0.1 0 -0.7 -0.9 -0.4
PALB2 16p12.2 16p 16p TSG 6.18E-06 discordant X 0.44 0.18 -0.1 -0.3 0.24 0.19 0.39 0.67 0.86 0.65 0.98 0.08 0.05 -0.1 -0.1 0.07 0.08 0.1 0.28 0.63 0 0.17 0.32 0 0.06 0.12 0.33 0.7 0.25 0.46 0.55 0.44 0.35 0.41 0.47 0.66 0.27 0.42 0.48 -0.1 -1 -1.2 0.5 0 -0.5 -0.4 0.16 -0.1 -0.2 -0.2 0 0.03 0.38 -0.1 -0.1 -0.1 -0.2 0.12 -0.1 0.05 -0.4 -0.5 -0.9 -0.3 -0.4 -0.1 -0.1 -0.1 -0.2 -0.2 0 -0.1 -0.1 -0.8 -0.4 -0.3 -0.4 0 -0.4 -0.4 -0.3
USP9X Xp11.4 Xp Xp 2.43E-05 concordant 0.06 0.14 0.27 0.19 0.14 -0.1 0.08 0.63 0.4 0.05 -0.1 0.31 0.57 -0.3 0.15 0.27 0.11 -0.1 0.29 0.42 0.08 0.58 0.32 0.03 0.21 0.4 0.6 0.88 0.4 0.33 0.25 0.26 0.39 0.26 0.51 0.69 -0.1 0 -0.3 0.01 0.37 0.29 0.01 0.44 0.06 0 -0.4 -0.3 -0.3 -0.4 -0.1 -0.1 0 -0.1 -0.5 -0.1 -0.2 -0.2 0.29 0.48 0.21 0.41 0.33 0.35 0.05 0.06 0.06 0.1 0 0 0 0 0.05 -0.2 -0.1 -0.7 0 0.22 -0.5 -0.4 -0.1
NCOR1 17p11.2 17p 17p TSG 3.26E-05 concordant OK 0 0 0.01 0.05 0 -0.1 0.25 0.21 0.16 0.42 0.19 -0.3 -0.3 -0.3 0.17 0.02 -0.1 -0.5 -0.1 -0.3 -0.4 -0.3 -0.4 -0.2 -0.2 -0.4 0 0 0.18 0.2 0.21 -0.2 -0.2 0.03 -0.4 -0.1 -0.1 0 0.33 0.29 -0.2 -0.2 -0.4 -0.7 -0.4 -0.5 -0.7 -0.6 -0.8 -0.8 0.23 0.3 0.24 -0.2 -0.1 -0.2 0.05 0 0.31 0.44 -0.2 0.31 0.06 0.17 -0.2 0.05 0.02 0.24 0.09 0.11 0.27 -0.2 0.08 0.51 0.13 0.41 0 0 0 0.22 -0.2
FGFR2 10q25.3-q26 10q 10q P 4.61E-05 discordant X -0.8 0 0 0.14 0.01 0.13 -0.2 -1 -0.6 -0.7 -1.7 0.19 1.24 -0.1 0.07 -0.3 0.04 0.06 0.13 -0.2 0.51 0.19 0.06 0.41 0.11 -0.2 -0.8 -0.6 -0.2 -0.1 -0.2 -0.1 -0.1 0.23 -0.3 -0.2 -0.1 -0.1 -0.2 -0.5 -0.5 -0.3 0.06 -0.7 0.11 0.17 1.65 0.7 -1 -1.2 0.35 0.29 0.09 -0.3 0.16 -0.3 0.18 0 0.07 0.45 0.21 0.58 0.72 0.39 -0.5 0.06 0.36 0.36 0.19 0.13 0.22 0.18 0.27 0.02 0.14 0.2 0.36 0.52 0.39 0.01 0.17
NF2 22q12.2 22q 22q TSG 7.09E-05 discordant OK -0.8 -0.1 0.21 -0.1 -0.1 -0.3 0 -0.5 -1 -0.5 -0.7 0.44 0.42 0.36 0.03 0.04 0.17 0.3 0.45 -0.1 0.02 0.14 0.07 0.3 0.18 -0.2 -0.2 -0.4 -0.2 0.05 0.02 0.01 0.1 0.26 0.13 0.31 0.12 0.43 0.26 0 0.64 -0.2 -0.6 -0.5 -0.1 -0.1 -0.3 -0.3 -0.6 -0.7 0.29 0.03 0.53 0.15 0.63 -0.2 0 -0.3 0.12 0.39 -0.1 0.08 0.32 0.24 0.18 -0.1 0.19 0.32 0.34 0.43 0.29 0.21 -0.1 0.35 0.19 0.42 0.39 0.15 -0.2 -0.1 -0.1
CDH1 16q22.1 16q 16q TSG 8.59E-05 discordant OK 0.21 0.27 -0.2 0.18 0.26 0.38 0.55 0.51 0.77 0.05 0.91 0.36 0.1 0 -0.2 -0.4 -0.4 -0.1 0.28 0.16 0 -0.1 -0.1 -0.2 -0.1 0.18 0.19 -0.1 0.06 0.47 0.33 0 0.2 1.05 0.53 1.01 0.55 0.54 0.39 0.32 -0.1 0.52 -0.4 0.04 -0.1 -0.1 -0.5 -0.7 -0.4 -0.4 -0.5 -0.8 -0.3 0.42 0.07 -0.2 -0.2 0.07 -0.1 0.28 -0.2 -0.1 -0.4 -0.1 0 0.19 -0.3 -0.3 -0.5 -0.4 -0.5 -0.1 0.2 0.13 -0.1 0.33 -0.1 -0.4 -0.4 -0.2 -0.2
ECT2L 6q24.1 6q 6q 9.25E-05 concordant -0.6 0.12 -0.1 0.03 -0.1 0.34 0.33 -0.9 -0.2 -0.6 -0.4 0.32 0 -0.6 0.06 0.04 -0.4 0.13 0 -1.1 0.49 -0.2 -0.5 0.44 -0.1 -0.2 -0.8 -1.1 -1 -0.6 -0.1 -0.5 0.36 0.26 -0.7 -0.4 -0.2 0.73 1.33 0.21 -1.2 0.99 -0.4 -0.7 -0.1 -0.6 0.55 0.39 -0.7 -1.2 0.22 0 0.36 -0.5 -0.2 0.51 0.29 0.53 -0.1 0.07 0 -0.2 -0.5 -0.1 -0.1 0.28 0.21 0.54 0.39 0.72 -0.2 0 0.44 1.07 0.41 2.79 -0.2 0.66 0.03 -0.2 0.64
CNOT3 19q13.4 19q 19q TSG 0.000137 discordant OK -0.2 -0.2 0.73 -0.1 -0.2 -0.1 -0.2 1.05 -0.2 -0.1 -0.5 -0.1 0 -0.6 0.53 0.19 0.17 0.16 0.01 -0.2 -0.4 0.08 -0.2 0.5 0.47 -0.4 0.13 -0.6 0.11 0.04 0.23 0.1 0.18 -0.3 -0.2 -0.1 0.37 -0.5 -0.9 0.01 1.64 1.3 0.27 -0.4 0.39 0.11 -0.2 0 -1.3 -1.7 1.17 0.83 0.38 -0.5 -0.2 0.17 0.26 0.71 0.22 0.38 0.24 0.78 0.69 0.3 0.3 0.39 0.57 0.39 0.49 0.5 0.06 0.39 0.39 0.37 0.36 -0.5 -0.2 0.09 -0.6 -0.3 0
PDGFRA 4q12 4q 4q P 0.000595 discordant X 0.29 -0.3 -0.1 -0.1 0.29 0.07 0.27 0.37 0.78 0.33 1.39 0.34 0.06 0.03 0.23 0.32 0 0.3 0.28 0.49 -0.1 0.48 0.6 0.14 0.22 0.32 0.27 0.25 0.07 0.09 0.17 -0.1 0.5 0.85 0.13 0.39 0.19 0.41 0.22 0.11 -0.4 -0.4 0.04 -0.1 -0.1 -0.1 -0.1 -0.2 -0.3 -0.3 -0.1 -0.3 0 -0.1 0.08 -0.2 0 -0.4 -0.2 -0.2 -0.2 -0.5 -0.8 -0.7 -0.1 -0.2 0.05 0.11 0.12 0.18 0.33 0.06 0.17 0.07 -0.4 0.13 -0.1 0.11 0.15 0.01 0
BRCA2 13q13.1 13q 13q TSG 0.000635 concordant OK -0.4 -0.2 -0.2 -0.3 -0.2 -0.1 0.05 -0.3 -0.1 -0.3 -0.2 0.11 0.26 0.53 0 0.02 -0.1 -0.3 -0.1 0 0.33 0.31 0.46 -0.2 -0.1 0.27 0.55 0.99 0.63 0.22 0.3 0.35 0.72 0.53 0.14 0.26 -0.4 -0.2 -0.3 0.16 0.91 0.77 -0.1 0.15 -0.8 -0.3 -0.7 -0.6 -0.3 -0.5 -0.4 0.02 -0.2 0 -0.6 -0.2 -0.5 0.09 -0.1 -0.1 0.03 -0.4 0.06 -0.2 0.13 0.04 -0.3 -0.2 0 -0.2 -0.1 -0.1 -0.2 -0.4 -0.3 -1.4 0 -0.5 -1 -0.7 -0.5
ZNF217 20q13.2 20q 20q P 0.000817 discordant OK -0.9 -0.4 -0.3 0 0.03 0 -0.1 -0.6 -0.1 -0.6 -1.5 0.55 0.65 0.64 -0.5 0.12 0.13 -0.5 0.35 -0.5 -0.8 0.15 -0.5 0.07 -0.1 -0.1 -1.3 -1.2 -0.4 0.21 0.01 -0.2 -0.3 -0.1 -0.2 0.72 1.14 0.61 -1.3 1.23 0.42 -1.2 0 -0.6 0.73 0.55 -0.3 -0.1 -1.4 -2.4 0.07 0.27 0.59 0.06 0.54 -0.3 0.17 0.05 0.23 0.58 0.35 -0.4 0.16 -0.5 0.5 -0.3 0.38 0.1 0.08 0.09 -0.1 0.12 0.2 1.67 -0.5 3.03 0.17 0.29 0.51 -1.3 0.18
CBLB 3q13.11 3q 3q P 0.001376 discordant OK 0.73 0.47 0.06 0.21 0.19 -0.3 0.15 0.32 0.34 0.11 1.63 -0.1 -0.3 0 0.14 0.12 0 -0.4 -0.4 -0.2 -0.3 -0.1 0.02 -0.2 -0.2 -0.1 0.16 0.35 0.02 0.05 0 -0.1 0.5 0.33 -0.1 0.25 0.23 -0.3 -0.7 -0.2 0.06 0.25 -0.1 0.24 -0.1 -0.1 -0.3 0 0.07 0.08 0.21 0.2 0.11 0.12 -0.3 -0.3 0.37 -0.3 -0.2 -0.2 -0.2 0.1 -0.4 0.2 -0.1 0.1 -0.2 0 -0.2 -0.1 -0.8 -0.3 -0.2 0.02 -0.1 -0.6 -0.3 -0.3 -0.3 -0.2 -0.3
MEN1 11q13 11q 11q TSG 0.001806 discordant OK 0.08 0.32 0.12 0.29 0.22 0.25 0.38 0.67 0.55 0.12 0.39 0.45 0.66 -0.2 0 0.4 -0.2 -0.4 -0.1 0.61 -0.2 0.16 0.31 -0.5 0.2 0.41 0.49 0.91 0.18 0.39 0.45 0.23 0.65 0.2 0.38 0.39 -0.4 -0.6 -0.4 0.12 0.29 0.53 -0.7 -0.1 -0.4 -0.2 -0.2 -0.4 -1.2 -1.1 0.02 0.24 0.31 0.19 -0.8 -0.2 0.14 0.27 0.21 0.03 0.2 0.25 0.09 0.35 -0.1 0.27 -0.5 -0.2 0.08 -0.1 -0.6 -0.4 -0.3 0.07 -0.6 -1.6 -0.8 -0.7 -1 -0.9 -0.9
AKT2 19q13.1-q13.2 19q 19q P 0.002236 discordant X -0.3 -0.1 0.76 -0.2 0.13 0.27 0 -0.1 -0.1 0.05 -1.6 0.05 0.19 -0.1 0.26 0 0.05 0.05 -0.1 0 -0.2 0.35 0.08 0.46 0.05 0.64 0.09 -0.1 -0.4 0.3 0.14 0 0.37 -0.3 -0.1 0.18 0.3 -0.8 -1.3 0 -0.6 -0.1 -0.2 -0.2 -0.1 0.15 -0.2 -0.2 -1.6 -1.6 -0.1 -0.1 -0.2 -0.4 -0.1 0.15 0.53 0.74 0.11 0.85 0.25 0.91 1.57 0.94 -0.1 -0.1 0.27 0.42 0.48 0.33 0.18 0.11 0.31 0.79 0.5 -0.6 -0.3 0.01 0 -0.2 -0.1
NOTCH2 1p13-p11 1p 1p P 0.002819 concordant OK 0.45 0.03 -0.1 0.08 0.05 -0.2 -0.2 0.92 0.73 0.68 1.03 0.03 0.07 0 0.28 0.24 0.21 0.55 0.28 0.31 -0.1 0.14 -0.2 0.12 0.39 0.14 0.36 0.5 0.27 0.31 0.27 0.23 0.34 0.13 0.18 0.61 -0.5 -0.1 -0.6 0.2 -1.1 -1.3 -0.1 -0.1 -0.2 -0.3 0.18 -0.1 0.01 0.03 -0.1 0.08 0 -0.1 -0.3 -0.1 0 -0.2 0 -0.1 -0.4 -0.2 -0.6 0 -0.5 -0.3 -0.1 0.04 0.1 0.01 -0.2 0 -0.2 -0.1 -0.3 -1 -0.1 0 0.15 0.27 0.31
KDM6A Xp11.2 Xp Xp TSG 0.002975 discordant X -0.1 0.12 0.03 0.21 -0.1 -0.2 -0.5 -0.2 0.13 0.17 -1.5 0.26 0.53 0.32 0 -0.1 -0.1 -0.3 -0.8 -0.4 -0.3 0.19 0 0.12 -0.1 0 -0.3 0 0.14 0.15 0 0.06 0.17 0.07 -0.3 0.27 -0.2 0.61 0.13 -0.3 0.03 0.21 -0.2 -0.1 0.15 0 -0.5 -0.3 0.11 0.06 0.46 0.28 0 0.12 0.27 0.09 0.15 0.57 0.1 0.3 -0.1 0.49 0.11 0.05 -0.2 -0.3 0.21 0.29 0 0 0.06 0.09 0.11 -0.2 0.24 0.08 0.08 0.13 0.2 0.06 0.08
KRAS 12p12.1 12p 12p P 0.006222 discordant OK -0.5 -0.3 0 0.14 0.22 0.34 -0.3 0.18 -0.2 0.11 -0.3 0.34 0 -0.2 -0.2 -0.5 -0.3 0 -0.9 -0.5 -0.4 -0.5 -0.4 -0.4 -0.4 -0.3 -0.1 0.37 -0.2 -0.3 -0.1 -0.1 -0.6 -0.1 -0.4 0.26 0.21 -0.1 0.22 -0.2 0.4 -0.7 0.24 0 0 -0.2 -0.9 -0.3 -0.1 0.05 0.05 0 0.11 0.07 0.16 0.38 0.49 0.14 0.16 0.07 0.11 0.44 0.38 0.24 0.65 0.27 -0.2 0.33 0.03 0 0 -0.2 -0.2 -0.4 -1 0.07 -0.3 0 0.24 0.27 -0.3
PIK3CA 3q26.3 3q 3q P 0.007082 concordant OK 0.38 -0.1 0.06 0.12 -0.1 -0.2 0.1 0.88 0.29 0.18 -0.6 0 0 0.02 0 0 0 -0.1 0 0.14 -0.3 0.12 0.35 0 -0.2 -0.2 0.29 0.37 0 0.4 0.26 0.19 -0.1 0.25 0.06 0.43 0.27 0.25 0.5 0.14 0 -0.1 0.13 0.17 -0.2 -0.2 0.1 0.11 0.06 0 -0.1 0.02 0.19 0.26 -0.2 -0.3 -0.1 -0.3 0.3 0.38 0 0.2 0.14 0.11 -0.4 -0.2 -0.2 0.03 -0.2 -0.1 -0.4 -0.1 -0.1 0.04 -0.1 0.01 -0.1 0.07 -0.2 -0.2 -0.2
MDM2 12q13-q14 12q 12q TSG 0.007378 discordant OK -0.2 0.18 0.2 0.03 0.05 0.28 0.2 0 -0.3 0.04 -0.2 -0.1 -0.5 0 0.16 0 0.12 0.39 0.45 0.02 0 -0.1 0.13 0.07 0.09 0.12 0.4 0.2 0.19 0.23 0.04 0.08 0.41 0.55 0.04 0.3 0.06 0.3 -0.3 0.17 0.03 -0.3 -0.2 0.07 -0.2 -0.1 -0.1 0.13 0.05 0.11 -0.1 -0.2 0.07 0.22 -0.2 -0.5 -0.4 -0.2 0.02 0.33 -0.1 0.16 0.26 0.46 0.03 0 0.04 0.12 0 0.06 0.03 0 0.04 0.08 0 -0.5 -0.1 -0.3 -0.4 -0.3 -0.1
PBRM1 3p21 3p 3p TSG 0.007579 discordant OK 0.41 0.14 -0.2 0.25 0.19 -0.2 -0.1 0 -0.2 0.1 0.08 -0.3 0 0.01 -0.2 -0.6 -0.2 -0.3 -0.4 -0.4 0.08 0.08 -0.1 -0.1 -0.2 -0.7 -0.2 -0.3 0 0.2 0.38 0.13 0.05 0.47 -0.1 0.16 -0.2 0.4 0.29 -0.1 0.54 0.39 0.27 -0.2 0.09 -0.1 -0.5 -0.1 -0.3 -0.3 0.46 0.02 -0.1 -0.1 0.19 0.29 0.32 0.39 0.26 0.28 0 0.25 0.26 0.09 0.06 -0.1 0.41 0.4 -0.1 0.06 0.21 0.37 0.03 -0.1 0.21 0.2 0.07 0.02 0.17 0.01 0.01
PRDM1 6q21 6q 6q 0.011611 discordant 0.49 0.19 0.65 0.8 0.51 0.92 0.82 0.5 0.24 0.72 0.55 0.31 0 -0.1 0 0.01 -0.1 -0.9 -1.2 -0.2 -1.3 -0.1 -0.7 0 -0.6 0.25 0 -0.7 -0.3 0.13 -0.3 0.29 0.26 0.33 -0.5 0 -0.3 -1.8 -0.9 -0.4 -1 -1.1 -0.2 -0.7 -0.4 -0.7 0.05 0.26 -0.2 -0.4 0.5 0.49 0 -0.2 -0.2 0.09 0.1 0 0.67 0.89 0.47 0.79 0.7 0.93 0.14 0.08 0.02 0.37 0.03 -0.1 0.03 -0.3 0.03 -0.2 0.02 -0.4 -0.4 -0.3 0.62 0.41 -0.6
CUX1 7q22.1 7q 7q TSG/P 0.015998 discordant 0.06 0.14 0.25 0.16 -0.1 0.02 0 -0.5 -0.1 -0.2 -0.6 -0.2 0.07 -0.3 -0.1 -0.1 0.02 -0.1 -0.4 -0.2 0.05 0.24 0.27 0.44 0 0.01 -0.1 -0.1 -0.1 -0.1 0.05 0.13 0.06 0.37 -0.3 0.18 0.09 -0.2 -0.1 0.17 0.12 0.25 0 0 0.09 0.34 0.68 0.37 -0.6 -0.5 0.15 0.19 0.12 0.06 0.09 0.16 0.19 0.09 0.21 0.26 -0.1 -0.2 -0.1 0 -0.1 -0.6 0.12 0.2 0.1 0.02 0.05 0.15 0 0.01 0.21 0.33 -0.1 0.16 0.51 0.39 0.33
CCND1 11q13 11q13 11q P 0.017202 concordant OK 0.65 0.32 0.14 0.11 0.08 0.47 0.34 0.55 0.44 0.1 0 0.42 0.71 -0.2 0.93 1 0.94 0.35 0.17 -0.2 0.43 0.63 0.22 0.22 1.03 -0.2 -0.8 -0.1 0 0.43 -0.4 0.02 -0.1 -0.4 -0.4 -0.5 1.93 -0.7 -1.2 -0.1 -1.2 -0.3 1.54 0.11 0.54 0.05 -0.3 -0.1 0.18 0.07 0.48 0.63 0.55 -0.2 0.35 -0.2 -0.3 -0.2 0.31 0.36 -0.2 0.4 0 0.29 0.22 0.05 0.61 1.16 0.82 0.58 0.18 0.4 0.21 1.19 0.76 -1.4 0 0.79 1.12 1.21 1.34
PMS2 7p22.1 7p 7p TSG 0.017598 discordant X -0.3 -0.4 -0.2 -0.1 -0.3 -0.3 0.11 -0.8 -0.3 0.17 -0.8 0.38 0.46 -0.5 -0.1 0 -0.3 -0.4 -0.8 -0.1 -0.4 0.24 0.59 0.36 -0.5 0.09 -0.4 -0.4 0.69 0.34 -0.3 0.11 -0.2 -0.1 -0.4 0.8 -0.9 1.03 -2.3 -0.2 -1.6 -0.5 -0.3 -0.5 0.11 0 -0.4 0 -0.8 -0.6 0.04 0 0.19 -0.2 -0.5 -0.2 0.04 -0.2 -0.3 0.05 -0.2 -0.1 -0.1 -0.1 0.19 -0.2 0.23 0.79 -0.2 -0.2 0.37 0.34 0.32 -0.8 -0.3 -1.7 0 0.38 0.46 0.63 0.21
MED23 6q22.33-q24.1 6q 6q TSG 0.018997 discordant OK 0.34 -0.2 0.89 0.66 0.25 0.23 0.15 0.15 1.39 0.41 0.35 0.4 -0.1 -0.1 -0.5 0.19 -0.1 0.07 -0.8 0.46 0.32 -0.1 0.04 0.33 0 0.15 0.04 -0.4 0.61 0.42 0.16 0.32 0.95 1.2 0.71 0.85 0.42 0.31 0.47 0.86 1.78 0.2 0.18 -0.1 -0.8 -0.7 0.14 0.86 0 0.04 -0.1 -0.1 0.21 0.13 -0.5 -0.7 -0.1 -0.2 1.67 0.5 -0.1 0.46 0.79 -0.3 0.53 0.66 0.02 0.17 0 0.11 -0.3 0 -0.1 0.9 0.13 0.84 -0.2 -0.3 -1 -0.8 -0.5
CREBBP 16p13.3 16p 16p P 0.020457 concordant OK -0.3 -0.3 -0.4 0 0 -0.2 0.17 -0.2 0.33 -0.5 0.06 0.13 0.31 0.22 0.05 0 -0.1 0.31 0.17 0.24 0.06 0.03 0.06 0 0.02 0.01 0.04 -0.1 -0.1 0.01 0.32 0.01 0.48 0.59 0.2 0.42 0.46 0.19 0.36 0 0.12 0.09 0.34 -0.1 -0.1 0.03 0.28 0 -0.3 -0.1 -0.1 -0.1 -0.1 -0.1 0.06 -0.1 0 -0.7 0.57 0.35 0.03 -0.2 0.49 -0.1 0 -0.1 -0.1 0.01 0.04 0.14 0.02 0 -0.1 0.13 -0.1 -0.6 -0.2 -0.1 -0.2 -0.2 -0.2
MYC 8q24 8q 8q P 0.02139 concordant OK -0.4 -0.2 -0.6 0.04 0.15 0.23 0.46 -0.3 -0.4 0 -0.1 -0.4 0.04 -0.3 0 0 0.01 0.27 1.29 0.2 -0.2 0.2 0.41 -0.1 0.16 0.56 0.49 0.63 0.26 0.32 0.36 0.67 0.99 0.69 0.72 0.98 0.71 0.59 1 0.16 -0.2 0.22 0.11 0.32 0.05 0.05 0.08 -0.2 -0.7 -0.5 0.04 0.25 0.26 0.17 0.04 0.02 -0.1 -0.1 -0.2 -0.1 -0.1 -0.2 0 -0.2 -0.2 0.06 -0.1 0.06 0.02 0.07 0.15 0.04 0.14 0.49 0.09 -0.3 -0.3 0.13 -0.1 -0.2 -0.5
CCNE1 19q12 19q 19q P 0.02543 discordant X 0.09 0.15 -0.1 0.04 -0.2 -0.1 0.23 0.41 -0.1 0.46 -0.5 0.15 -0.1 -0.3 0 0.08 -0.1 -0.1 0.03 0.01 -0.1 0.07 0.81 -0.2 -0.1 -0.1 0.34 0.29 -0.1 0 0.04 0 0.13 0.11 0.48 0.56 0.32 -0.2 0.15 -0.1 -0.1 0.2 -0.1 0.16 -0.4 -0.1 -0.4 0.03 0 0 0.13 0.24 0.38 0 -0.4 0.16 0.22 0.34 0 0.3 0.07 0.1 -0.1 0 0.15 -0.4 -0.1 0.04 0.01 0 0 -0.1 0 0.03 -0.1 -0.2 -0.3 -0.3 -0.3 -0.4 -0.3
EGFR 7p12 7p 7p P 0.03096 discordant OK -0.7 -0.2 -0.5 -0.2 -0.3 -0.2 0.95 -0.8 -0.5 -0.8 -0.6 0.08 0.03 0.14 0.12 0.05 0.15 0.34 0.58 0.24 0.16 0.64 0.69 0.44 0.25 -0.1 -0.2 -0.2 0.02 -0.1 0.09 0.34 0.34 0.28 -0.1 0.09 -0.2 0 0.09 -0.3 0.64 0.89 -0.2 -0.3 -0.3 -0.1 -0.2 -0.2 -0.5 -0.5 -0.2 0.05 0.09 -0.3 0.02 0.46 0.4 0.75 0.12 0.08 -0.5 0.35 0.5 0.1 0.39 -0.2 0.08 0.14 0 0.12 -0.2 0.07 0.02 0.24 0.06 -0.3 0 0.35 0.29 0.25 0.04
PREX2 8q13.1 8q 8q P 0.033033 discordant OK -0.4 0 -0.5 -0.3 -0.3 -0.3 -0.2 -0.7 -0.6 -0.5 -0.9 -0.3 -0.2 0.05 -0.1 0.05 -0.2 0 0.13 0.3 0.15 0 0 -0.1 -0.1 -0.2 0.13 0.37 0.06 -0.2 -0.2 0.14 0.58 0.65 0.59 0.76 0.09 0.75 0.79 0.01 -0.1 -0.2 0 0.07 -0.3 -0.2 -0.5 -0.6 0.08 0 -0.2 -0.1 -0.1 -0.1 -0.3 -0.2 -0.2 -0.2 -0.3 -0.3 -0.4 -0.1 -0.1 -0.4 0 0.1 -0.2 -0.1 -0.2 -0.1 -0.2 -0.3 -0.2 -0.3 -0.3 -0.3 -0.1 0.36 -0.4 -0.4 0.03
ERBB2 17q11.2-q12 17q 17q P 0.033727 concordant OK 0.66 0.58 0.15 0.55 0.43 0.53 0.42 1.01 1.02 0.62 0.88 2.75 3.12 2.49 0.3 0.15 0 1.81 2.31 0.49 0.53 0.47 0.51 0.14 0.32 2.72 0.27 -0.1 -0.5 0.52 0.56 0.06 2.49 0.48 -0.5 0.08 -0.4 0.04 0.03 0.32 -0.2 -0.1 -0.2 0 0.22 0.02 -0.3 -0.1 -1.5 -2 0.32 0 0.37 -0.2 -0.3 -0.3 -0.1 0 0.35 0.35 0.02 0.09 -0.1 0.25 0.35 0.11 0.31 0.38 0.24 0.47 -0.2 0.53 0.47 1.09 0.13 -0.9 0.94 0.3 -0.9 -0.7 1.24
CASP8 2q33-q34 2q 2q TSG 0.039284 discordant OK -0.1 0.11 0.4 -0.3 -0.3 0.04 0.54 0.04 0 0.57 0.56 0 -0.3 0 0.22 0.06 0.21 0.23 0.34 0.36 -0.1 0.22 0.54 0.07 0.15 0.44 0.21 0.22 0 0.31 0.39 0.44 0.78 0.39 0.23 0.03 0 -0.5 -0.4 -0.1 0.23 -0.5 0.09 0.17 0 -0.1 0.08 0.1 -0.6 -0.6 -0.1 0.02 -0.1 -0.1 -0.3 0.42 0.71 0.47 0.22 0.42 0.14 0.19 0 0 -0.3 -0.1 0 0.03 0.03 0 -0.3 0.03 0.02 0.3 -0.2 -0.8 -0.2 0.05 -0.7 -0.5 -0.2
MAP3K1 5q11.2 5q 5q P 0.048998 discordant X 0.7 0.35 0.17 0 0.01 0.31 0.15 0.45 0.74 0.43 2.15 -0.5 -0.4 -0.4 -0.1 -0.1 0.03 -0.1 -0.5 -0.3 -0.3 0.36 -0.2 -0.5 -0.5 -0.9 -0.3 -1 0.28 0.16 0.13 -0.2 -0.8 0.57 -0.9 -0.9 0.28 -0.1 -0.1 0.14 0.42 1.39 0.3 0.13 0.44 0.3 0.04 0.08 0.25 0.29 -0.1 0 -0.2 -0.1 0.22 -0.2 -0.4 0 -0.2 -0.4 -0.6 -0.5 -0.9 -0.4 -0.1 0.22 0.15 0.01 0 0.07 0.16 0.23 0.21 0.73 -0.1 1.03 -0.6 -0.3 0.51 0.45 -0.9
